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7Foreword by the EMCDDA Director
This is the third strategy and work programme since the EMCDDA’s recast Regulation 
in 2006. It is being launched at a challenging and uncertain time with regard to the 
financial and institutional environment that we face in Europe. Whilst recognising 
this, I am pleased that we can launch a programme that I believe is forward-looking 
and that will deliver increased value from the work of the EMCDDA and its partners.
I can make this commitment because this strategy is built on sound foundations. 
Over the last six years, we have put in place the management, organisational and 
technical structures necessary for the agency to move up to the next level in terms of 
its capacity to provide Europe with a state-of-the-art information base to inform policy 
and action. At the heart of the strategy is a commitment to quality and value, and 
over the next three years we intend to improve not only the scientific standing of our 
outputs but also their usefulness and accessibility.
Our previous work plans have on occasion been criticised for being ambitious and I 
make no apologies for the fact that we remain ambitious in setting the goals for our 
work. However, this strategy and work programme is also a pragmatic and realistic 
one. We recognise the need to set priorities and review our approaches and to 
ensure that they remain relevant to the challenges we face. Across Europe, resources 
for interventions and data collection are coming under increasing pressure. The drug 
situation itself is evolving at considerable pace. New demands are being placed 
on the agency at a time when the need to maintain a comprehensive overview of 
the European drug situation remains with us. We must therefore strike a balance 
between maintaining our core information activities and ensuring that new important 
areas are adequately addressed. In order to achieve more within a limited budget, 
efficient working practices must be rigorously pursued and less productive activities 
eliminated. This perspective informs all aspects of our new strategy and work 
programme.
Three top-level commitments will underpin our work in 2013–15. First, we will focus 
on providing a relevant, timely and responsive analysis to the drug situation. We 
have refined our reporting on the past; we need to ensure that our work is relevant 
for the contemporary debate and that it keeps pace with developments. Part of the 
purpose of understanding today’s drug situation is to anticipate the problems of the 
future, and a forward-looking perspective is therefore essential. Second, we will 
focus on efficiency and ensuring that maximum value is derived from our activities. 
This will be assured by strengthening our strategic and operational capacity and 
developing a more performance-based organisational culture. It will also require 
more interdisciplinary work and for us to streamline our outputs to ensure that they 
are fine-tuned to the needs of their target audiences. Our third commitment is to 
communication and a customer-orientated approach. We have always developed 
tailored outputs for our target audiences but we must keep pace with an evolving 
communication landscape and the changing culture on how information is utilised. 
We need to adapt our strategy not only to meet the growing expectations of our 
current information consumers but also to be ready to meet their future needs.
I am proud of the achievements we have made that make this work programme 
possible and I am excited about the opportunities it provides to further fulfil our 
mission. I am confident that this multi-year work programme will significantly 
contribute to providing the information and analysis necessary for a better response 
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to Europe’s drug problem. I know, in making this commitment, that I can rely on a 
team in Lisbon that is committed, competent and highly professional. We benefit 
from an active and informed Management Board and the guidance we receive from 
a Scientific Committee comprising some of Europe’s leading scientists working in the 
drugs area. Beyond this, however, I am also acutely aware that our success is built 
upon the close partnership we have with experts working across Europe, and, in 
particular, the Reitox network of national focal points. Our work also benefits from 
the active and ongoing support we receive from the European Commission, from a 
close working relationship with our sister EU agencies and the partnerships existing 
with international organisations working in our area. Therefore both a commitment 
to, and the recognition of, the value of partnership and effective joint working will 
remain a defining element of the EMCDDA approach and inform all aspects of our 
work and planning.
Wolfgang Götz
Director, EMCDDA
9
10
EMCDDA 2013–15 strategy and work programme
Context
Continuity and a commitment to progress remain at the heart of the EMCDDA’s 
approach to planning. The bedrock on which this three-year strategy and work plan 
rests is the recognition that the achievements the agency has made since its inception 
have been delivered by maintaining clarity of purpose, technical rigour and a long-
term vision. Our role is to provide Europe with a scientifically sound and comparable 
picture of the drug situation and to achieve this we have worked incrementally to 
develop high-quality tools and reporting mechanisms that are appropriate to the 
diverse national contexts in which we work. Partnership is essential for success in 
this endeavour. As the European hub for drugs information we can act as a catalyst 
and facilitator for national endeavours but cannot replace them. The success of the 
EMCDDA depends on the existence of its expert networks, in particular the Reitox 
network of national focal points (NFPs), which enables us to maintain ongoing 
dialogue with researchers and practitioners across Europe.
With commitment to continuity as the necessary starting point of the work 
programme, we recognise that both internal and external factors will inevitably 
shape the agency’s work over the coming three years. We must ensure that our 
work is responsive to the challenges of monitoring the contemporary European 
drug situation. This the third triennial work programme since the EMCDDA’s recast 
Regulation in 2006. As ever, we propose an ambitious set of objectives for our 
forthcoming work. We can do this because of the sound foundations laid in the 
previous two three-year strategies that have provided us with the administrative, 
technical and organisational infrastructure necessary to develop our work further. 
We know we are doing this at a difficult time. Across Europe resources for 
interventions and data collection are under increasing pressure — and this is at 
a time when the drug situation itself is evolving at considerable speed and new 
demands are being placed on the agency. We face, therefore, significant challenges 
for the next three years and a balance has to be struck between maintaining core 
information resources and ensuring that new important areas are adequately 
addressed. The agency needs to maximise the value of its work and increase the 
overall impact of the system with regard to its outputs, whilst at the same time 
recognising that capacity to report is finite and in some areas may need to be scaled 
down. This work programme has been tailored to address this difficult landscape in 
a realistic manner. It provides a strategic and substantive framework for providing 
a comprehensive state-of-the-art understanding of the European drug situation that 
is of direct relevance to policies and practice. It explicitly takes into account the 
need to set clear priorities, protect core activities and focus resources to achieve 
maximum benefits. Performance is ensured by placing emphasis on implementing a 
comprehensive internal planning, performance management and quality assurance 
system.
A necessary first step to conceptualise this strategy and work plan was to take stock 
of the progress made to date and to scope out the medium- and long-term challenges 
we face. To guarantee a sound framework for the agency’s future activities, our 
preparatory work has been informed by internal and external reviews and dialogue 
with key stakeholders and partners. These reviews, intended to complement 
the formal consultation processes that take place prior to adoption of the work 
programme, have allowed more voices to be heard during the formative phase. 
Preparatory activities included a dialogue with the Scientific Committee and the 
Reitox community, as well as invited input from key institutional partners and external 
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stakeholders. A public consultation exercise by means of the EMCDDA’s website was 
also undertaken. We have conducted an internal systemic review of reporting tools 
and analytical processes and taken into consideration the emerging findings from the 
current external evaluation of the agency’s performance. Developments in the recent 
evaluation of the EU drug strategy and action plan have been followed closely too, 
as have early developments on a new EU policy framework. This approach has 
ensured that this strategy is informed by the lessons that can be learned from our 
past work; the views of our partners and stakeholders; and Europe’s current and 
future information needs. Importantly, coherence emerged from the reflection process 
on a number of fundamental issues, which gives the agency confidence that its 
planning is on track and in line with current realities, expectations and information 
needs.
12
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I. Information and analysis for policy and action:  
the EMCDDA’s strategy and vision for 2013–15
Introduction: the EMCDDA’s role in 2013–15
The utility of a holistic analysis of the European drug situation
The agency has been founded on the basic precept that a better understanding of 
the drug situation, in all its aspects, is a prerequisite to developing effective policies 
and actions. The drugs issue is not a simple one. Conceptually, it encompasses a 
range of behaviours and related health, social, criminal justice and ethical issues. 
Methodologically, it is equally challenging as it requires observing complex, 
hidden and often stigmatised behaviours. Interventions take place across a broad 
continuum, spanning prevention, treatment, harm reduction, social reintegration, 
legal control, market intervention and enforcement. Patterns of drug use and 
drug markets are dynamic, constantly changing and influenced by wider social 
phenomena. Against this backdrop, any information source is likely to be partial and 
any conclusion drawn needs to be carefully framed. The EMCDDA’s unique strength 
is that it is a multidisciplinary agency that addresses all aspects of the drug situation.
We have been successful in working with EU Member States to significantly improve 
the quality and comparability of information available in many areas. Improving 
data quality is an ongoing task but we are now in a position to give greater 
emphasis to using the data for analytical purposes. This will allow us to test the 
available information sources against one another and produce analysis that is not 
only scientifically sound and sensitive to the complexity of the subject matter but 
also geared to identifying the bigger issues necessary to inform the policy debate 
at European level. We believe that we can better exploit our unique position as the 
central reference point for drug information in the EU by ensuring that maximum 
analytical value is derived from the data collected.
Thematic priorities: the conceptual building blocks for this work programme
This strategy and work plan is built around five thematic areas that are priorities for 
data collection and reporting. Together, these cover the agency’s core tasks and form 
the conceptual building blocks needed to assemble a comprehensive understanding 
of the European drug phenomenon.
The priorities in the recast regulation are: (a) monitoring the state of the drugs 
problem, in particular using epidemiological indicators, and monitoring emerging 
trends; (b) monitoring the solutions applied to drug-related problems; (c) providing 
information on best practices in the Member States and facilitating information 
exchange among them; (d) assessing the risks of new psychoactive substances 
and maintaining a rapid information system; (e) developing tools and instruments 
to help Member States to monitor and evaluate their national policies, and the 
Commission to monitor and evaluate European Union (EU) policies. Their importance 
was highlighted in the recent external evaluation and in comments received 
from key stakeholders during the preparation of this document. Supply reduction 
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activities are an explicit part of our existing mandate to comprehensively monitor 
the drug situation. However, the need to scale up the monitoring of supply-side 
issues has become increasingly apparent in recent years. The EMCDDA has always 
collected supply data, as they are a key conceptual element for monitoring both 
the drug situation and the responses to it. However, to date there has not been the 
systematic approach adopted for demand-side information, which is a weakness 
in the current EU information system. Work is already being undertaken with the 
European Commission (EC) to define three new key indicators in the supply area. 
The importance of this task has been underlined by the external evaluators and 
emphasised by the European Commission and other stakeholders in the informal 
consultation process launched prior to drawing up this strategy; that lends further 
weight to the level of priority awarded to it here.
At a glance: Overview of the EMCDDA 2013–15 conceptual framework for 
monitoring Europe’s drug problem 
Translating information into evidence: meeting Europe’s changing information 
needs
Collecting data is not an objective in itself; the information collected needs to 
be put to work. This requires sound analysis and interpretation as well as an 
integrated communication strategy that delivers outputs configured to the needs 
of our different target audiences. This work programme has been designed to 
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improve our performance in both these areas. We give emphasis to extending 
our quality assurance procedures into the area of statistical analysis and data 
manipulation. We will introduce new checks and balances to assure the quality and 
transparency of EMCDDA computations, and a quality assurance framework will 
underpin the agency’s outputs. The new communication strategy will improve the 
relevance and coherence of the agency’s portfolio of products. We need to keep 
pace with developments in the way information is utilised and exchanged and for 
this reason we have focused on improving our online presence. Online tools and 
resources will be enhanced to match the changing expectations of data users. 
This development will be complemented by a streamlined annual report that will 
deliver a more accessible overview of the drug situation and provide a window 
to a comprehensive set of online data and analysis. As well as better serving the 
information needs of policymakers, more attention will be given to producing outputs 
relevant for the scientific and practice community. Greater prominence will therefore 
be given to identifying guidelines, evidence synthesis and dissemination of best 
practice examples. The role of NFPs as active communicators of national data in 
contrast to passive data providers will also be strengthened. Finally, the needs of 
non-specialised data users will be better met through developing improved basic 
summary material, interactive online tools and source material for students and 
educators.
Principles for driving progress and guiding change
Beyond the substantive priorities, our work is informed by three transversal principles 
that will drive progress and guide change. These principles shape and focus 
activities and are interpreted in the detail found in each of the substantive work 
programme areas described in the second part of this document. These guiding 
principles are by necessity overarching and complementary, and re-emphasise a 
commitment by the agency to ensure that all aspects of the EMCDDA’s work remain 
on track and remain focused on delivering quality.
A commitment to providing a relevant, timely and responsive analysis of the 
drug situation
Even within the priority areas outlined above, the choice of topics for analysis is 
large and it is always possible to increase the level of detail for data collection and 
reporting. Given that the capacity of the reporting system is finite, it is important 
to ensure the coherence of the system as a whole. We focus therefore on areas of 
particular analytical relevance and pay greater attention to defining (and limiting 
where necessary) the scope of activities. We have selected those areas most 
important for elaboration at EU level and those areas that match explicit information 
needs. Building on work already in progress, we will regularly review how data 
collection efforts inform analysis and outputs in order to concentrate efforts on those 
areas that are productive and identify areas where investments are not paying 
dividends. We will also focus on different topic areas across the three-year period to 
maximise the capacity of the system to address important issues whilst respecting the 
need to constrain the annual reporting burden and not overstretch limited resources.
To be useful for policy, information needs to be technically robust and timely. These 
two requirements do not always sit well together, as the time taken to assemble 
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sound data sets often results in a considerable delay in their becoming available. 
On the other hand, the validity or reliability of information that is rapidly available 
may be questionable. However, we recognise that the information we collect is 
of greater value if it can be quickly disseminated and that there is a parallel need 
to follow up more rapidly on emerging trends. This need is driven by the current 
speed at which the European drug situation is evolving and by the consumers 
of our information, who expect a rapid response to questions on important new 
developments. This situation has two important implications for our work. First, we 
will further streamline reporting processes to facilitate the earlier annual reporting 
of main findings. Second, based on learning from ongoing trend-spotting work 
and activities connected with implementing the European early warning system 
on new psychoactive substances, the agency will continue to invest in developing 
approaches to more rapidly identify and report on emerging trends. We will 
do this in an overall context of being proactive in bringing together diverse sets 
of information, informing analysis with contextual data, grading evidence and 
synthesising data. Such an approach can allow interpretation to be made from 
imperfect data and allow uncertainty to be reduced even where it cannot be 
eliminated. This illustrates how we are developing the role of the agency as a centre 
for analysis in addition to being an information hub. Moreover, by better exploiting 
the communication links existing with the Reitox network, and the opportunities 
provided by the regular contacts the EMCDDA has with experts across Europe, 
a more dynamic qualitative approach to investigating and cross-validating new 
developments will be pursued. Methodological developments will accompanied by a 
series of short, online products (EMCDDA updates) that will be launched in 2013.
A growing challenge for the EMCDDA analysis is to reflect the complex nature of 
contemporary patterns of drug use in Europe. A key issue here is that polydrug 
use now predominates. This is not only important for understanding the health and 
social consequences of drug use but also central to informing the development and 
targeting of responses. Therefore, and fully respecting the mandate provided by 
the recast regulation, special attention will be given wherever possible in this work 
programme to analysis and reporting on the impact of the co-consumption of multiple 
psychoactive substances.
The capacity to be responsive to new developments is an important requirement 
for a sound, mid-term planning approach and we have left flexibility in the work 
programme to answer such needs. Whilst as far as possible the information 
requirements of a new EU drug strategy have been anticipated in this document, 
adjustments may still need to be made once the new EU strategy becomes available. 
Similarly, work is under way (at the time of drafting this document) to provide a new 
legal basis for tasks conducted under the EU mechanism for early warning and risk 
assessment for new psychoactive substances, and here again implications for the 
EMCDDA’s future work are not known. Moreover, some capacity has to be retained 
to allow flexibility in the substantive day-to-day work of the agency. For this reason, 
the existing internal rapid response mechanism will be maintained to allow us to 
respond effectively to important ad hoc information requests. Given the dynamic 
nature of both patterns of drug use in Europe and the European drug market, the 
work programme will be reviewed as needed to ensure that it remains fit for purpose 
and that all important topic areas are being adequately addressed.
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A commitment to efficiency: deriving maximum value from activities and 
investments
We are committed to continuing to improve the agency’s performance with respect 
to its core business whilst also extending activities in strategically important areas. 
In an environment of fixed, or even declining, resources this means that every 
aspect of our work has to be informed by a need to gain efficiency and derive 
maximum value from efforts made. This can be achieved by rationalising processes 
so that the most productive activities are given priority; eliminating non-productive 
work streams; maintaining a clear focus on objectives; and seeking added value 
and synergy wherever possible. This principle will be supported by an improved 
planning, monitoring and quality assurance framework, which will be the basis for 
introducing a more performance-based culture for the agency’s work. We will review 
all substantive activities to ensure that the methods used are optimal with respect 
to the expected results and could not be achieved better by another approach. 
We will pay attention to both process and substance, to ensure maximum value is 
obtained from the technical meetings held by the EMCDDA. We will continue to 
use technology to support networking, improve communication and facilitate data 
submission. We will pay particular attention to ensuring efficient data management 
processes and selecting the appropriate medium for outputs.
We recognise that the difficult economic situation facing many countries across 
Europe will have both a direct and indirect impact on the EMCDDA’s work. Directly, 
data collection is always a secondary task with respect to measures taken to address 
drug problems. However, we believe that sound analysis is critical to ensuring that 
investments made are well targeted and that the most appropriate interventions are 
supported. It will be more important than ever for the EMCDDA to provide Member 
States with a realistic, scientifically sound and achievable set of core information 
tools for efficiently monitoring the drug situation. Equally important is the work to 
identify good practice, guidelines and disseminate knowledge of effective actions 
so that maximum value can be derived from the existing European evidence base. 
Indirectly, drug problems tend to be more pronounced in communities facing 
social and economic difficulties. In a climate in which investment in interventions is 
becoming more difficult to secure, and with possibilities of increased vulnerability 
to drug problems, our work to monitor and report on developments becomes more 
important than ever.
The EMCDDA does not work in isolation, and drug issues represent an important 
element in the bigger picture of protecting public health, security and community 
safety in Europe. We regard pursuing successful partnerships and seeking synergy 
wherever it can be found as the key to efficiency; that is why we give partnership 
and joint work such a high priority in this strategy. Core activities here include 
working closely with EC services to ensure synergy with financial initiatives; 
supporting research, capacity building and service development; and data sharing 
and dissemination. We will strengthen the sound partnerships we have with 
European agencies whose mandates partially cross over with the EMCDDA’s such 
as the European Centre for Disease Prevention and Control (ECDC), Europol, the 
European Police College (CEPOL), the European Medicines Agency (EMA) and 
Eurojust. We have planned a number of joint publications and projects that benefit 
from the commitment across the family of European agencies to work together to 
avoid duplication of tasks, rationalise activities and generate added value. We 
would like to highlight a major analysis of the drug market conducted in partnership 
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with Europol, closer data sharing and new joint publications with the ECDC and 
Eurojust, and a new working arrangement with the EMA to meet the requirements of 
the European pharmacovigilance (PhV) legislation. Beyond our work within Europe, 
we will continue to maintain good links with appropriate regional information 
systems, such as that operated by the Organisation of American States (CICAD), 
and work as provider of European data and expertise within the terms of established 
practice with relevant international agencies, in particular the United Nations Office 
on Drugs and Crime (UNODC), the World Customs Organization (WCO), the World 
Health Organization (WHO) and Interpol.
The EMCDDA also maintains close links with a number of European research groups 
working in areas relevant to the agency’s mandate. Of particular importance here 
is the link that exists with the European School Survey Project on Alcohol and Other 
Drugs (ESPAD) group. The network provides a valuable source of longitudinal data 
on drug and alcohol trends. Following a recent agreement to scale up cooperation, 
the EMCDDA will increase its support for ESPAD activities during the course of this 
new three-year work programme, which will over time be hosted by EMCDDA.
It is also recognised that the operation of some national Reitox focal points may 
come under pressure because of the current financial situation. In line with the 
proposals contained in the external evaluation and with standing rules and 
procedures, the EMCDDA might take a more differentiated approach to supporting 
and mentoring NFPs. This could result in EMCDDA support being focused on those 
focal points that need it most.
A commitment to communication and a customer-orientated approach
Communication is one of our core activities supporting our role as information 
agency and helping us further our reputation as the reference point on drugs in 
Europe. We regard communication not as an isolated function at project-end, but 
as an integral part of the agency’s scientific and technical activity. We define our 
customers as all those individuals and bodies interacting with the agency. We are 
faced with a rapidly changing communication landscape in which consumers pick 
and choose the type of information they want, how and when they want it, and the 
quantity they need. Such dynamism requires us to respond with timely content, be 
attentive to emerging needs and deliver our information using an ever-expanding 
set of communication tools. Our commitment to do this is guided by the integrated 
communication strategy launched in 2012, which sets out the fundamental principles 
for communicating our knowledge and presents the tools available to build and 
nurture relations with the agency’s stakeholders, target audiences and partners.
The channels we have at our disposal include the web, publications and print 
products, events and conferences, the media, audiovisual material and social media. 
These multiple, and often converging, information channels demand strong synergies 
between the different specialities in the agency’s communication team. Such cross-
functional working will allow the agency to shape and repurpose content efficiently 
and mobilise a mix of options, with the ultimate goal of maximising the impact for 
the customer.
The EMCDDA website is the agency’s primary means of communicating across all 
target audiences and is key to reinforcing the agency’s profile as the primary source 
of drug information in Europe. We need to concentrate over the next three years 
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on better delineating and developing our web-based products and to fit them into 
our quality assurance framework. We will work to strike a better balance between 
online and printed products. Moreover, the streamlining of some product lines and a 
redesign of others will be necessary to ensure content relevance and coherence for 
agency results.
At a glance: Overview of EMCDDA product lines in 2013–15
Information and analysis for policy and action
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II. From strategic vision to getting results: the EMCDDA’s 
work programme for 2013–15
Introduction
This operational section of the document presents the agency’s goals and specific 
objectives for the next three years organised by main area of work. It provides a 
clear framework for ensuring that the strategic commitments set out above are put 
into practice.
Priority interventions and key expected results have been defined for each main 
area. If not otherwise specified, the timeframe for achieving the results is by the end 
of 2015, the last year of this programming period.
We have developed this multi-year operational plan from a thorough internal 
planning exercise. The annual work programmes will provide the detailed planning 
of activities and resources to implement the priority interventions and achievement of 
key results.
This multi-year approach will ensure continuity in planning of the agency’s resources 
over the next three years and will facilitate the monitoring of results. It will be 
supported by an integrated performance measurement system, to be developed and 
implemented by the end of 2015.
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Main area 1: Data collection, analysis and quality assurance
Overview
To fulfil its mandate, the EMCDDA has developed an integrated and detailed 
reporting system, based around data collection, analysis and quality assurance tools 
and processes. A main component of this system is a national reporting package 
developed and implemented in close collaboration with the NFPs. This reporting 
package provides data delivered through a set of standard instruments via Fonte 
(the online data collection system of the agency). The reporting package is updated 
annually to meet changing information needs.
Each year, an important aspect of our work revolves around data submission and 
management tasks, including the production of templates, data validation and further 
development of the Fonte system. This work ensures a methodologically sound, 
coherent and efficient annual reporting exercise.
During 2013–15, we will improve the performance of the reporting system based 
on the findings of a top-level review of reporting tools and practices, which was 
launched in 2011. The results of this exercise will be used to strengthen the overall 
coherence of the reporting package by introducing a stronger quality assurance 
framework for the processes and statistical procedures used.
In parallel with the revision of the overall national reporting package, we will 
also improve data collection instruments. Amongst the significant developments 
foreseen are improvements to the tools for collecting information on treatment 
provision including the implementation of the new treatment demand indicator (TDI) 
protocol (v. 3.0). This protocol will be accompanied by improved functionality for 
data submission, enabling an increased number of Member States to submit data 
automatically. EMCDDA staff will continue to provide bespoke support to focal 
points that wish to develop automated data submission capacity. In addition, we will 
implement a new data collection and analysis strategy for reporting on drug use in 
the prison setting. We will also introduce improved or new data collecting tools in 
the areas of problem drug use (PDU), supply responses and policies.
We will improve the EMCDDA’s analytical processes, focusing on cross-referencing 
different data sources. This approach extends descriptive analysis to more than one 
indicator, provides a method for validation and coherency checking, and can help 
identify appropriate methods for estimating missing data.
Quality assurance is a priority for all areas of our work for the next three years. 
In the area of data collection, we will revise and streamline existing quality 
assurance procedures. Different approaches are required for the different types of 
data collected. Efforts will be made to improve, formalise and codify the informal 
processes used for ensuring quality. For the next three-year period, this will include 
the development and adoption of a statistical quality assurance framework along 
with agreed measurable indicators of achievement. We will revise the structure of the 
quality reports that provide feedback to the NFPs and a new format and tools will be 
implemented.
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Goal: A coherent, reliable and valid data collection system, underpinned by a 
quality assurance framework 
Specific objective 1.1: Improve data collection instruments and processes
Priority interventions Key results
Revise the reporting system to improve 
coherence and efficiency 
• New processes implemented
• National reporting package and 
guidelines, adopted by the EMCDDA and 
the Reitox NFPs 
Implement new data collection exercises, 
based on revised tools 
• Revised data collection tools in place, 
reflecting strategies for treatment and 
prisons
• Revised templates and new data collection 
exercises implemented in the areas of TDI, 
PDU, supply and policy
• Increased capacity for automatic 
submission of TDI data
Maintain and further develop (as required) 
the Fonte reporting system and data 
warehouse
• Systems for data collection operational 
Specific objective 1.2: Strengthen and develop the quality assurance framework to 
support data collection, statistical analysis and data reporting
Priority interventions Key results
Develop a cross-indicator approach to 
improve data validation and analysis
• Integrated indexes developed
• Thematic data tables available for analysis 
and coherence checking
Review, rationalise and develop existing 
quality assurance measures around data 
collection 
• Improved validity and reliability of the 
data received
• Overall quality assurance framework in 
place
• Improved quality reports 
Develop a statistical quality framework for 
the analysis, manipulation and reporting of 
data within the EMCDDA
• Improved transparency, appropriateness 
and utility of estimations
• Framework for creating and documenting 
quantitative estimates in place
• System of ratings obtained through expert 
opinion for semi-structured, qualitative 
information improved and documented
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Main area 2: Monitoring and understanding drug use and problems: 
key indicators and epidemiology
Overview
The epidemiological monitoring of the drug situation is at the heart of the EMCDDA’s 
work. These data provide the long-term, standardised time series analysis that is 
an important part of the added value provided by the European drug monitoring 
system. The task is to quantify, and describe over time, developments in the drug 
situation as well as the health and social consequences arising from drug use. 
We have developed standard methodologies to allow Member States to collect 
information in a sound and comparable way, which are centred on the five 
epidemiological key indicators. These indicators provide information on prevalence 
and patterns of use (through surveys and studies of special populations) and 
consequences (with a focus on infectious diseases and drug-related deaths). The 
data provided by the key indicators, when combined with research and contextual 
information, provide a valuable insight into developments in drug problems in 
Europe. As this area of work is now relatively mature, we are able to shift emphasis 
from developmental activities to more analytical ones, thereby increasing the value 
obtained from investments in this area. Moreover, as the analytical insights obtained 
from the indicators are enhanced when they are used in combination, efforts will 
be focused on moving from an individual indicator perspective to a multi-indicator 
platform to inform EMCDDA analysis and reporting.
One of the main purposes of understanding patterns of drug use and their 
consequences is to facilitate the targeting, design and evaluation of policies and 
interventions. To reflect this objective, many of the analyses we will undertake 
combine epidemiological data with response-side information and there is an 
emphasis on transversal and coordinated work. The key indicators provide the 
empirical building blocks on which many of these more complex analyses depend.
By placing emphasis on analysis, we are by no means neglecting our commitment 
to ensure high-quality data generation and efficient processes. Our priorities in this 
area are described in detail in the previous section. However, it is important to note 
here that the expert networks supporting each indicator are of critical importance for 
ensuring data quality and for gaining analytical insight. We will revise the current 
expert meeting format to give more opportunity for discussion and analysis. Where 
possible, we will hold expert meetings sequentially, with the objectives of, on the one 
hand, delivering efficiency savings and, on the other, allowing crossover sessions 
to be held in which experts from different disciplines can work together. As part of 
the commitment to quality assurance, we will better capture the findings from expert 
meetings and make them available more rapidly. The key indicator expert groups 
will also play an important role in the scientific conference planned for 2015.
Timeliness is a key aspect of any monitoring system. As many of the data sources 
on which the key indicators are based rely on annual registry data, some lag in 
reporting is unavoidable. Nevertheless, as already noted, we will review internal 
and external processes to ensure that they are as efficient as possible and that they 
accord with the new reporting perspectives outlined in the communication strategy. 
We will also pursue a more proactive approach to engaging with experts attending 
technical meetings to ensure latest developments can be taken into account. Indicator 
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data will also be used to complement trend-spotting activities and in forecasting 
exercises, to ensure that the analysis addresses contemporary information needs. It 
is appropriate for some areas to undertake more rapid data collection exercises, for 
example to address potential outbreaks of drug-related diseases or unusual clusters 
of drug-related deaths or medical emergencies.
Reflecting the move towards increased online dissemination, we will reorganise 
the EMCDDA’s epidemiological information. This will require reviewing the 
existing resources for reporting summary and national data, methodological 
information and analysis. The Statistical bulletin will remain an important vehicle 
for presenting quantitative epidemiological data but its content and linkage to other 
online resources will be enhanced. We will rationalise the handling of national 
epidemiological data across the web platform, and new interactive options for 
data manipulation and summary analysis will be introduced in close collaboration 
with the NFPs. A new set of short, focused analyses will be produced to showcase 
standalone elaborations of key data sets. These analyses provide a flexible tool for 
exploiting the insights gained from the information collected.
Data collection takes place at the national level, as does much analysis, and 
technical capacities vary across Member States. This is why we provide significant 
support to data collection activities, data harmonisation and analytical work at 
the national level. The EMCDDA can act as a catalyst for improved performance 
in this area. For example, we will continue to support the data lab concept, in 
which common analysis is performed based on harmonised data sets and common 
guidelines. The key indicator implementation assessment we conducted in 2012 
will highlight the countries most in need of technical support and we will focus our 
efforts on them. Similarly, we will conduct analytical exercises that are relevant to 
only some countries on a restricted basis in order to assure efficient use of resources. 
As the EMCDDA’s data collection model is becoming internationally renowned, 
and in order to support both EU and international efforts to improve reporting 
capacity globally, we will work on an implementation model for drug information 
systems based around the common standards developed by the EMCDDA. This will 
complement the existing manual on focal point building by providing a ‘tool box’ for 
collecting drug information informed by EU and international standards and good 
practice.
With the European drug problem constantly evolving, it is important that the 
epidemiological approaches used by the EMCDDA keep pace and remain fit for 
purpose. Among the new developments planned are activities to ensure that codes 
and questions remain appropriate to new drugs and emergent patterns of drug use. 
As polydrug use and stimulants become a more important part of the drug situation, 
we have planned developmental work to explore how data on acute drug-related 
emergencies can be collected. We will also conduct an assessment of options to 
improve the coverage of the drug-related infectious diseases (DRID) indicator to 
infections not acquired by injection but where drug use is a mediating factor.
The consumption of multiple classes of psychoactive substance (polydrug use) is 
now common across the EU and this has important implications for both the harms 
associated with different consumption patterns and the design of responses. This kind 
of consumption is particularly challenging for traditional monitoring approaches, 
which are often based on a single substance. We will analyse key indicator data 
from general population surveys, treatment attendance and drug-related deaths to 
provide insights into the prevalence and patterns of polydrug use in the EU. This 
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information will be useful for developing a typology of polydrug use patterns and 
associated risks and harms. To take account of changing consumption patterns, 
we have already reviewed the PDU indicator to make the tool more discriminating 
across drugs. These activities will result in improved quantification of the European 
drug problem in the 2013–15 period. The TDI, which provides a window on 
those accessing treatment services, has also been revised to report better on the 
characteristics, drug use and risk profiles of those seeking help for drug-related 
problems. The experts for each indicator will be tasked with ensuring a regular 
critical review of the EMCDDA’s approach to ensure that it remains consistent with 
the drug situation and reporting needs.
We plan a number of new analyses over the work programme, which will be 
detailed in the annual planning exercise and selected on the basis of data 
availability, analytical value and topical relevance. We will give special attention to 
the issue of psychiatric co-morbidity with a topical review exploring the association 
between mental health problems and drug use, and how this can have an impact on 
the outcomes of treatment and the potential for recovery. How social, individual and 
environmental factors are associated with drug use will also form part of a major 
new scientific monograph.
Goal: Provide an integrated and insightful overview of the European drug situation 
by enhancing analysis of the epidemiological key indicators, including cross-
indicator analysis and combined analysis with other sources of information, 
while ensuring the quality of the information collected by Member States and the 
EMCDDA 
Specific objective 2.1: Ensure progress in the methodological development of the 
epidemiological key indicators (KIs)
Priority interventions Key results
Maintain and further develop 
methodological tools for KI implementation
• Improved general population survey (GPS) 
guidelines for:
 – online surveys and handling non-
response
 – new European Model Questionnaire 
(EMQ) module on ‘new drugs’ and 
updated module on alcohol and 
medicines
• New guidelines for PDU (concepts and 
estimation) including stimulant use, 
cocaine, polydrug use, cannabis and 
alcohol
• Improved implementation of TDI by
 – implementation of new TDI 
prevalence module
 – mapping of data availability on 
health and social correlates (pilot 
exercise)
• Feasibility of using hospital emergencies 
as information source on health 
consequences (in collaboration with EWS) 
explored
• Guidelines refined and coverage of DRID 
indicator extended (if feasible)
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Priority interventions Key results
Cooperate on methods and exchange 
information with other EU and international 
institutions (within mandate and where 
appropriate) 
• Data exchange, cross checking, 
harmonisation and identification of 
redundant processes
• Active participation in relevant technical 
initiatives at EU level
Scale up cooperation with ESPAD project • ESPAD field-test trials in preparation for the 
2015 survey supported
• Joint analysis conducted
Rationalise and improve web-based 
information on the drug situation
• Integrated KI overviews linking 
methodological information, summary 
data and national data sets 
Specific objective 2.2: Support the implementation of the key indicators by the 
Member States, through ongoing monitoring and provision of technical guidance 
and training
Priority interventions Key results
Actively monitor implementation of KIs and 
identify implementation needs 
• Triennial/annual assessment reports, 
including needs assessment
Provide expert advice and training to 
support the countries, as needed 
• Training programmes developed and 
delivered as required, based on identified 
needs 
Support key indicator implementation • Updated EU questionnaires map
• Proposal for harmonisation of national 
GPS surveys developed
• Estimates based on new PDU protocol 
available for at least 50 % of Member 
States
• TDI protocol (version 3.0) implemented: 
completeness of the data assessed and 
implementation issues addressed
• Support for countries in setting up new 
mortality cohorts
• Improved data quality through increased 
use of DRID toolkit 
Support the implementation of KIs in third 
countries and international efforts to improve 
reporting capacity (for details see Main area 
8: Cooperation and collaboration with key 
partners) 
• Training and advice activities conducted, 
materials produced and implementation 
supported (where appropriate)
Specific objective 2.3: Maximise the value of key indicator information through 
analysis to provide a comprehensive, relevant and multi-source understanding 
of contemporary patterns of drug use, trends and related health and social 
consequences
Priority interventions Key results
Organise European key indicator expert 
meetings
• New expert meeting concept implemented
• Operational platform for methodological 
development and analysis 
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Priority interventions Key results
Improve exploitation of data through 
standalone and cross-indicator analysis
• Structured analysis plans to support the 
annual reporting package analyses and 
other outputs
• Data showcase — set of focused analyses, 
produced online with graphics and 
supporting notes (issues chosen for topical 
and analytical relevance)
• Patterns and trends in drug use 
elaborated: technical/scientific papers 
providing a more detailed analysis (with 
responses/contextual data and research 
information)
• Updates on topics of importance 
(rapid follow-up to important emergent 
information needs or outbreaks) including 
regular update on trends in behavioural 
surveillance indicators 
Develop guidelines for and promote analysis 
at national level and act as a catalyst for 
multi-country analysis 
• Guidelines developed and tested
• New analyses conducted (standalone, 
data labs and multi-country)
Develop complex cross-epidemiological 
indicator analysis and analysis integrating 
epidemiological and responses indicators 
• In-depth topical reviews on psychiatric 
co-morbidities and opioid overdose 
(EMCDDA Insights series) 
29
From strategic vision to getting results
Main area 3: Monitoring demand reduction responses to drug-related 
problems
Overview
Describing demand reduction measures that Member States take to address drug 
problems is a core aspect of the EMCDDA’s work. These measures span prevention, 
treatment, harm reduction and social reintegration. Historically, the focus of our work 
in this area has been to provide a descriptive analysis of services available. We will 
now complement this approach by extending the analyses to cover the availability, 
coverage and quality of interventions delivered across Europe.
In the area of prevention, reporting is currently structured according to target group. 
We will continue to provide descriptive analysis of the availability of universal, 
selected and indicated approaches. However, reflecting emergent research findings 
we will place greater emphasis on analysing two relatively undeveloped areas 
that are likely to become important for future prevention work in Europe. These are 
environmental prevention and early intervention. We will explore these approaches 
to prevention through a mix of technical reviews, expert meetings and international 
collaboration. As these interventions often target a range of problem behaviours, a 
multidisciplinary approach will be necessary. We will bring together the EMCDDA’s 
work across prevention in a new state-of-the-art scientific review that will consider 
the latest understanding of risk factors for developing drug problems and how they 
inform the responses agenda (EMCDDA Monograph).
In the areas of treatment, harm reduction and social reintegration, our integrated 
and system-based approach to monitoring will be further developed. The focus will 
be on providing a holistic analysis of responses available and, where possible, how 
they may match differing needs. Systems of health provision and drug problems vary 
between countries and so such an integrated approach will make comparisons more 
informative. By uniting epidemiological data with information on the configuration 
and availability of responses, analysis can address the extent to which service 
provision is in line with estimated needs. This information can help Member States 
identify gaps in current service provision.
The EMCDDA will also develop guidance on how to scale up services in those 
areas where it is assessed to be deficient. A new approach in this area will be the 
development of system maps that will provide a consolidated geographical overview 
of responses available across Europe. This approach will enable us to monitor the 
availability and coverage of responses as part of an integrated model, thereby 
increasing its analytical value.
We will continue to prioritise our work to identify effective practice and encourage 
the sharing of information on ‘what works’. Ongoing dialogue with the scientific and 
practice community will ensure that we benefit from a state-of-the-art understanding 
of the available evidence for effectiveness. This dialogue will also provide a channel 
for disseminating results and increasing the overall impact of our work. The close 
collaboration we enjoy with the Cochrane group will be maintained and links with 
other relevant research bodies further developed. Inviting other appropriate networks 
to benefit from the EMCDDA’s technical infrastructure, thereby facilitating their work 
and allowing the agency to act as a hub for debate and information exchange, will 
provide added value.
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An important tool for disseminating information on effective programming is the Best 
practice portal. We will continue to develop the portal as a key European resource 
for collating examples of high-quality interventions. Future developments foresee a 
more important role for NFPs to ensure not only that national programmes of merit 
are identified, but also that learning is disseminated more effectively. The concept of 
best practice will also be extended to other response areas.
An understanding of what constitutes best practice is a critical requirement for 
developing sound standards and guidelines for service implementation. Working 
in close collaboration with the EC, the EMCDDA will continue to support the 
development of minimum quality standards and benchmarks across the drug demand 
reduction field. This work will build on the achievements of the EQUS (EU framework 
for minimum quality standards and benchmarks in drug demand reduction) project 
and support monitoring of the implementation of high-quality demand reduction 
programmes across the EU.
We will provide new state-of-the-art reviews of areas in which information resources 
are underdeveloped. In-depth topical reviews will be published addressing the 
treatment of cannabis-related disorders, responses to drug use in the prison setting 
and the treatment of hepatitis C among drug-using populations (EMCDDA Insights 
series). We plan to complement these reviews with practical guidelines to inform 
service development.
Goal: To support high-quality service development by producing information and 
analysis on demand reduction interventions and best practices 
Specific objective 3.1: To monitor prevention provision, implementation and outcomes 
and to improve reporting on important areas in which information resources are 
lacking
Priority interventions Key results
Provide an ongoing overview of drug 
prevention provision
• Comprehensive web resources available 
and key analyses conducted
• Up-to-date prevention profiles 
Develop analysis on environmental 
prevention factors 
• Analyses of social norms, school climate 
and parenting conducted and results 
integrated in prevention profiles
• Cross-analysis of indicators on social 
norms, alcohol and prevention policies 
Provide updated information on early 
intervention
• Evidence review on brief interventions for 
new target groups
• Prevention profiles and Best practice portal 
updated and expanded 
Develop information on coordinated 
programming
• Situation analysis on model coordination
• Technical review and compilation on 
programmes with multiple outcomes
• Self-assessment system for prevention 
policies
• Prevention profiles and Best practice portal 
updated and expanded 
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Specific objective 3.2: To improve the monitoring and analysis of treatment, harm 
reduction and social reintegration interventions and provide an integrated model for 
understanding service provision in Europe
Priority interventions Key results
Provide an ongoing overview of drug 
treatment, harm reduction and social 
reintegration
• Comprehensive web resources available 
and key analyses conducted
• Up-to-date responses profiles 
Implement the new treatment data collection 
and analysis strategy 
• Harmonised and comparable data on 
treatment systems across EU countries
• Improved capacity to develop treatment 
estimates at national level
• Feasibility/pilot study of TDI treatment 
facilities 
Conduct comparative analysis of drug 
treatment systems in Europe
• Conceptual framework for analysis 
developed
• Comparative analysis (Technical papers) 
Develop and test health and social responses 
target-and-indicator frameworks 
• Fully integrated responses profiles
• Reporting matrix/policy tool for treatment 
planning 
Support the reporting on public health 
provision in Europe and assess gaps
• Consolidated data for reporting on drug-
related issues for Dublin Declaration on 
partnership to fight HIV/AIDS in Europe 
and Central Asia
• Gap analysis and guidelines on scaling up 
interventions developed
 
Specific objective 3.3: To identify and support dissemination and knowledge 
exchange on best practices
Priority interventions Key results
Conduct state-of-the-art and evidence reviews • In-depth topical reviews on treatment 
of cannabis-related disorders, drugs 
and prison, and hepatitis C treatment 
(EMCDDA Insights series)
• Accompanying guidelines for best practice 
(EMCDDA Manuals series)
• State-of-the-art scientific review on drug 
prevention (EMCDDA Monograph series)
Further develop the Best practice portal • Best practice portal maintained and 
expanded to provide a comprehensive 
platform of resources 
Disseminate knowledge on best practice • Best practice promotion strategy 
implemented through tailored 
dissemination activities 
Conduct analysis to identify gaps in the 
evidence available for interventions 
• Information needs identified and 
guidelines prepared to inform and support 
future research and monitoring agenda 
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Main area 4: Monitoring drug supply and supply reduction 
interventions
Overview
The EMCDDA will reorientate its activity to fit better with the balanced approach in 
the field of drugs and to ensure that more high-quality analysis and information is 
available in the areas of drug supply and supply reduction. Information resources at 
European level are currently underdeveloped in these areas and comparable data 
and analysis are to a large extent lacking. The most significant developments in 
this area will be: first, to create a stronger information infrastructure by developing 
key indicators; and, second, to release a major new analysis of the European drug 
market, which will provide a policy relevant overview of this rapidly evolving area.
In order to address the lack of comparable and reliable data on drug supply in 
general, the EMCDDA was tasked by the European action plan on drugs (2009–12) 
to propose a set of key indicators in the fields of drug markets, drug-related crime 
and drug supply reduction. We have been working in close coordination with the 
EC to achieve this objective. The work undertaken during the 2010–12 period will 
culminate with the proposal of key composite indicators combining qualitative and 
quantitative data sets (‘subindicators’) in three core information domains. These 
key indicators will be developed in the 2013–15 programming period. This work 
will entail improving existing data collection mechanisms and establishing new 
measures. The NFPs will continue to play an important role as data providers in this 
area, although complementary sources of information also have to be explored. 
Methodological developments will be based on expert consensus, sensitive to 
reporting capacity and practice, and reflect priority information needs. Progress will 
be made incrementally and be dependent on availability of resources. Importantly, 
it will require the active support of Member States and recognition of the need for 
comparable data and reporting standards.
We will focus on developing data resources on drug seizures and drug production 
facilities. This information is a key input for the key indicators on drug markets and 
drug supply reduction. Moreover, under the new policy cycle described below, the 
EMCDDA together with Europol has been tasked with improving the quality of data 
analysis and reporting on these topics with reference to synthetic drugs.
The European drug market is dynamic, innovative and complex. In the area of 
synthetic drugs, developments are occurring particularly rapidly and analysis 
is complicated by the emergence of both new products and new methods of 
production. Beyond this, important changes have also been noted in the production 
and trafficking of established substances such as cannabis and heroin, which are 
likely to have important implications for the future. In recognition of this, the EC has 
identified the need for a comprehensive and integrated analysis of the European 
drug market. The EMCDDA, working jointly with Europol, will bring together the two 
agencies’ perspectives and information sources in a new major publication that will 
provide a strategic overview of the drug market and identify policy considerations. 
This analysis will build upon the positive experience of previous joint work and will 
complement other major outputs planned by both agencies.
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The EMCDDA has also been tasked, jointly with Europol, to implement activities 
under the operational action plan (OAP) for 2012–13 of the new policy cycle within 
the Council on Internal Security (COSI) of the European Union. The policy cycle is a 
structured priority-setting process for internal security. This process is a key strategic 
priority of the EU and therefore drugs are, and are likely to remain, a key issue 
on the European security agenda. We must therefore take the necessary steps to 
fulfil the tasks assigned to us under the OAP for 2013 and support the definition of 
priorities for the 2014 policy cycle that follows. The strategic market analysis to be 
produced with Europol may in time become a key instrument for helping to define 
security priorities on drugs in Europe, while the priorities of the policy cycle will be 
one of the inputs used in the planning and drafting of this document.
Successful reporting on supply reduction issues will require us to further develop 
synergies and partnership with other agencies working in this area. We will also 
have to invest in network building with the law enforcement and forensic science 
communities. Strong foundations already exist here. Maintaining the close working 
relationship we have with Europol will be critical for making progress at European 
level. In addition, we will develop our collaboration with Eurojust in order to 
support data collection and analysis of both quantitative and qualitative data on 
the European judiciary system. Links with the law enforcement community will be 
reinforced through the EMCDDA’s training activities in partnership with CEPOL. The 
EMCDDA and CEPOL have established a successful track record of collaborating to 
provide training on drug issues for European law enforcement personnel. Enhancing 
activities in this area will support building law enforcement capacity on drugs 
and gradually assist in the setting of drug law enforcement priorities in Europe. In 
addition, and importantly, it will help foster ongoing information exchange and 
build the trust, awareness and credibility necessary for working effectively with 
operational law-enforcement bodies.
In order to support analytical capacity building in this area we will need to establish 
a reference group composed of appropriate experts. This reference group will assist 
us in improving the quality, contextualisation and interpretation of data. The group 
will also be useful for understanding and keeping up to date with law enforcement 
strategies and practices. In addition it will support work to identify and report on 
emerging drug supply trends and drug supply reduction interventions. Substantive 
work to be undertaken includes a review of the tools, tactics and practices of 
specialised drug law enforcement units in Europe (‘drug squads’), which will build 
on an initial mapping exercise conducted in 2012.
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Goal: Provide the EC and the Member States with a comprehensive overview of the 
supply of illicit drugs into Europe and of the responses developed to respond to it
Specific objective 4.1: Develop European key indicators and complementary 
information resources for understanding drug markets, drug-related crime and drug 
supply reduction
Priority interventions Key results 
Launch the implementation of the key 
indicators in the areas of drug markets, drug-
related crime and drug supply reduction
• Mapping exercise on reporting practices 
in EU Member States and international 
partners
• Key elements of a standard definition 
for subindicators (seizures, production 
facilities, prices, purity and contents) 
identified
• Technical proposal for subindicators ‘Drug 
seizures’ and ‘Drug production facilities’ 
including a standard EU reporting 
instrument
Map drug supply reduction activities, 
focusing on ‘drug squads’
• Report on tactics and practices, based on 
survey results
Develop understanding of the judiciary 
system as a data provider and an actor of 
drug supply reduction
• Enhanced collaboration with Eurojust
• Conceptualisation of potential 
subindicators
Develop cooperation with external partners 
on supply indicators (EC, Europol, Eurojust, 
Interpol, WCO, Council of Europe/
Pompidou Group, CEPOL, UNODC, etc.)
• Coordination and data sharing on 
European indicators on drug supply 
Specific objective 4.2: Establish networks in the area of drug supply and supply 
reduction
Priority interventions Key results
Establish a European expert reference group 
on drug supply issues
• Reference group operational 
Scale up training for the law enforcement 
community and promote exchanges
• Training programmes developed and 
delivered with CEPOL
Specific objective 4.3: Produce a strategic analysis of drug supply and supply 
reduction in Europe
Priority interventions Key results
Strengthen capacity to report on 
international developments
• Support tool developed and implemented
Develop a data framework and input tools 
for drug seizures 
• Historical data reconstructed and 
integrated into Fonte
Produce strategic overview of drug markets 
in Europe
• Two strategic overviews on drug markets 
developed jointly with Europol
Produce joint analyses • Joint publication with Europol (cannabis or 
heroin)
• Joint publication with Eurojust
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Specific objective 4.4: Support the Internal Security Strategy of the European Union 
(COSI)
Priority interventions Key results
Carry out activities 1.5 and 1.6 under OAP 
for the policy cycle 2012–13
• Activities 1.5 and 1.6 implemented
Support the definition of the following policy 
cycle and implement the activities for which 
EMCDDA has taken responsibility
• Activities tasked within the OAP of the 
following policy cycle implemented
Develop cooperation with EU and 
international partners in the fields of home 
affairs and justice
• Coordination and information exchange
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Main area 5: Monitoring new trends and developments and assessing 
the risks of new substances
Overview
Providing timely information on new trends, together with an assessment of their 
potential to diffuse further and their possible impact, is one of the most important 
ways that the EMCDDA can deliver value from its work, and it can also play a 
critical role in facilitating timely and targeted interventions.
Activities conducted in support of the EU mechanism to monitor new psychoactive 
substances are important here. This mechanism established by Council Decision 
2005/387/JHA provides Europe with an early-warning system (EWS). Recent 
developments have seen new psychoactive substances becoming available at 
an unprecedented rate and the EWS has established itself as a real-time vehicle 
for multidisciplinary information exchange. The EWS is now used extensively by 
the forensic science community and by health and law enforcement professionals 
throughout Europe and is becoming recognised internationally as a valuable alert 
system and information resource. It is implemented by the EMCDDA and its partners 
in the Member States (the Reitox network) in cooperation with Europol, and with the 
active contribution of the EMA and the EC. Its success is derived in part from the fact 
that it sits within, and benefits from, the broader framework for information collection 
and analysis the agency has established.
There is no sign that future information needs in this area will diminish and, if 
anything, the demands placed on the EMCDDA in this respect are likely to grow. 
The phenomenon itself is also likely to become more complex. Catalysts here are the 
growing global capacity for cheap organic synthesis matched with entrepreneurs 
who have developed sophisticated marketing and distribution approaches. It 
would appear that hundreds of potential psychoactive agents are being actively 
investigated. Some overlap and there is interaction with the illicit drugs market, 
which is likely to increase over time with the introduction of more established control 
measures. To date, most new substances have targeted the recreational stimulants 
market but now there appears to be a growing interest in targeting chronic/
problematic drug users and in exploring the potential of psychoactive medicines. 
Work to monitor this rapidly evolving area is becoming an intrinsic element of our 
broader task to monitor developments in drug use in Europe.
A new legislative framework on new psychoactive substances is likely to enter 
into force during the course of this work programme. Consequently, the activities 
planned have been designed to provide continuity and at the same time anticipate 
future developments. We will continue to invest in the day-to-day work necessary for 
the real-time exchange of EWS information, as this is a key element of our current 
successful approach. As a main working tool of the EWS, the database on new 
drugs (EDND) will be updated and expanded, and, if required, risk assessment 
exercises will be carried out under the auspices of the EMCDDA’s Scientific 
Committee.
The information exchange and risk assessment mechanism and related data 
collection tools and guidelines will need to be adapted to the new legislative 
framework when it becomes available. It is likely that some of the activities 
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conducted in support of the early warning framework will need to be scaled up 
or adapted. For example, the need for a more proactive approach to information 
collection is widely accepted, as is the need for increased capacity and information 
sharing of forensic science data. The lack of research findings on epidemiological 
and toxicological aspects of new psychoactive substances is also a well-identified, 
recurring problem that could be addressed by well-targeted studies. We have 
therefore taken into account in our planning the fact that our activities will have to be 
reviewed.
Among the most pressing challenges hampering responses in this area are the 
practical difficulties of identifying the chemicals contained in different products — the 
value of sharing information in this area at EU level is clearly apparent. Our current 
response to this problem is ‘Project Match’, which is a pilot exercise to build up a 
set of chemical profiles of new products in a central database. Also troublesome is 
the availability of reference materials, which are of critical importance if toxicology 
laboratories are to identify new psychoactive substances. At the moment, there is no 
system for the synthesis and sharing of reference substances of new drugs, although 
we have made some attempts to include information on these topics in the current 
data exchange system. Clear added value can be derived from EU-level information 
dissemination in this area, and the EMCDDA will continue to support it.
Our planning is based on anticipating future needs, an awareness that activities will 
need to be shaped by the new legal framework, and the fact that they need to be 
commensurate with resource availability. The EWS is working at maximum capacity, 
and a significant expansion to the work conducted under this remit is difficult to 
envisage without adjusting the resources dedicated to it. That being said, the EWS 
demonstrates the value obtained from even a modest investment when activities 
are well coordinated and integrated. We believe that the current system provides a 
strong framework for developing additional capacities should they be required.
The EMCDDA will contribute towards meeting the relevant objective ‘Synthetic 
drugs, including new psychoactive substances’ of the operational action plan for 
2012–13 of the new policy cycle within the COSI. It is also possible that we will be 
given additional responsibilities in the new policy cycle period, and again the work 
programme may need to be adapted.
We will exchange data with the EMA as set out in Article 28c of the new PhV 
legislation. In consultation with the EC and in full compliance with the EMCDDA’s 
mandate, we will assess the feasibility of implementing a new conceptual framework 
for monitoring the misuse of medicines. Initial activities will focus on the misuse of 
controlled medicine used in drug treatment, trends in polydrug use and efficient 
information exchange.
The dynamic nature of drug use requires an equally dynamic monitoring response. 
The detection and monitoring of new trends therefore remains one of our key tasks, 
of which the EWS is but one element. We will work, therefore, to strengthen the 
EMCDDA’s system for monitoring and understanding new and emerging trends in 
drug use and drug markets. Integration with existing monitoring tools is important 
here, for example by ensuring that new codes are developed to include important 
new substances in established data collection mechanisms. New data sources are 
also required. We will continue to develop the use of accident and emergency room 
data, as this can provide a useful perspective of changes in the acute health effects 
that can accompany changes in drug consumption patterns. We will also continue to 
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explore the longer-term potential offered by sewage epidemiology and wastewater 
analysis for monitoring illicit drugs use in real time at the community level. We will 
continue to produce regular Internet snapshots using improved methodology to 
provide a more robust indicator of online activity.
We will track the use and availability of drugs such as ketamine, gamma-
hydroxybutanoic acid (GHB), benzylpiperazine (BZP) and mephedrone — 
which have been risk assessed, but are now of growing importance in the illicit 
marketplace — and of important substances such as fentanyl and methamphetamine, 
whose patterns of availability and use appear to be changing. To help achieve 
this, we will further develop our trend-spotter methodology, which provides a 
rapid and flexible source for proactively exploring new developments. Increased 
sensitivity to emerging trends will be generated through exploiting our role as an 
information broker in regular contact with networks across Europe and our network 
of focal points in all Member States. We will give more attention to discussing new 
developments in expert working groups and to improving mechanisms for collecting 
and validating the information that this kind of expert networking can bring. A 
number of city monitoring systems exist across Europe keeping their fingers on the 
pulse of local developments; our plans to network with these systems will add a 
dimension to our understanding of new developments in Europe’s drug situation.
The identification of new developments requires an appropriate dissemination 
strategy. The EMCDDA will continue to issue warnings when these are required 
through the Reitox focal points as well as other expert information networks and 
channels. We will maintain our rapid response teams to ensure that, when important 
information requests are received that require immediate action, they are managed 
effectively. To support timely dissemination, we plan to introduce a short online rapid 
communication product (EMCDDA updates).
Goal: To provide a timely and sound information and analysis platform for 
identifying emerging trends and threats related to new psychoactive substances and 
their risks, new patterns of drug use, and new developments in drug availability 
 
Specific objective 5.1: To ensure that the information exchange and risk assessment 
mechanism on new psychoactive substances is of high quality and implemented in a 
timely and efficient manner
Priority interventions Key results
Implement the provisions of the Council 
Decision 2005/387/JHA on the information 
exchange, risk assessment and control of 
new psychoactive substances
• Operational EWS and information 
exchange mechanism
• EMCDDA–Europol Joint reports prepared 
(if needed)
• Multidisciplinary, scientifically sound risk 
assessment procedure implemented (if 
requested)
• EMCDDA–Europol Annual reports on the 
implementation results 
Implement the provisions of Article 28c of 
the EU Pharmacovigilance (PhV) legislation
• Information exchanged with EMA and 
the EU PhV system on medicines and 
substances with medicinal properties
• EMCDDA use of the PhV web-based 
information system (EudraVigilance) 
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Priority interventions Key results
Build up a formal forensic science and 
toxicology network (in line with OAP for 
2012–13 of the new policy cycle within 
COSI) 
• Forensic science network operational
• Structured cooperation between EMCDDA 
and the European Network of Forensic 
Science Institutes (ENFSI)
Consolidate and improve the methodology 
for monitoring the Internet
• Internet snapshots conducted, data 
analysed and results disseminated
• Improved Internet-monitoring methodology
• Automatic tools developed and integrated
• Web mapping of new drugs/‘legal highs’ 
online shops developed
Support the consolidation of information 
on the content of products by implementing 
a tool that matches ‘legal high’ products 
to new psychoactive substances (‘Project 
Match’)
• Automated ‘Match’ tool implemented
• Database operational
Pilot monitoring of misuse of medicines (in 
the context of polydrug use and the EU PhV 
system)
• Better integration of information on misuse 
of medicines in EMCDDA reporting 
Assist candidate and potential candidate 
countries to prepare for future participation 
in the EWS and the Internet snapshot 
exercise 
• Training activities implemented at national 
and regional level (in context of IPA 4)
• Selected countries participating in 
snapshot exercise
Specific objective 5.2: To adapt and implement the information exchange and 
risk assessment mechanism on new psychoactive substances to new legal and 
institutional requirements
Priority interventions Key results
Assist the Commission and the Council with 
the preparation of new legislation to replace 
the Council Decision (if requested)
• EMCDDA contribution to the preparation 
of new legislation 
Implement the new legal instrument and 
adapt the existing networks, reporting and 
monitoring tools and instruments to new 
legal and institutional requirements
• All guidelines, procedures, processes and 
tools in line with new requirements
• Extended network operational
• New risk assessment guidelines published
Develop and implement the new EDND 
adapted to new legal and institutional 
requirements
• New database implemented and fully 
operational
• Public interface developed 
Specific objective 5.3: Facilitate the development of early responses to potential 
threats by strengthening the systems for identifying, tracking and understanding new 
and emerging trends in drug use, availability and adverse consequences
Priority interventions Key results
Improve monitoring of new drugs and links 
with epidemiology data sources and expert 
networks
• Internet survey on prevalence of new 
drugs/‘legal highs’ carried out
• Knowledge management system for 
internal and external networks 
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Priority interventions Key results
Increase the capacity to monitor emerging 
trends 
• Trend-spotter methodology improved and 
consolidated
• City network that helps assess emerging 
trends and threats established
• Local-level piloting of tracking tools and 
thematic case studies produced
• Rapid response team consolidated
Explore the potential of wastewater analysis 
as an indicator to estimate population drug 
consumption 
• Follow-up of meetings and pilot studies
• European Science Foundation (ESF) 
conference
• Technical proposal for an indicator 
developed
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Main area 6: Improving Europe’s capacity to monitor and evaluate 
policies
Overview
Since its creation, the EMCDDA has monitored various aspects of drug policies 
including drug laws, drug strategies and action plans, drug policy coordination 
bodies, drug policy evaluation mechanisms and drug-related public expenditure. The 
information needs and data availability in these areas differ and therefore different 
strategies have been developed to describe and report on each element.
A database (ELDD) and network of legal correspondents constitute the main 
resources supporting the EMCDDA’s reporting on drug laws. This has allowed the 
development of thematic analyses on topics such a penalties for drug use, threshold 
quantities, regulations for substitution treatment and control measures for new 
psychoactive substances. We will continue with this approach and have built in some 
flexibility to allow the EMCDDA to be reactive to requests for new policy analyses. 
Among the planned new thematic publications is an analysis of typical trafficking 
penalties in the EU Member States.
The monitoring of national drug strategies and national coordination bodies has up 
to now relied exclusively on data collection activities with the NFPs. In the coming 
years monitoring will be enhanced with the use of external experts and some small-
scale studies planned. Different aspects of national drug strategies, such as the 
linkage between research and policy, will also be examined. In addition, analyses 
will explore the different drug policy models that exist in Europe and internationally.
Another development planned to improve the quality of the data and analysis in 
the drug policy area will be to strengthen the existing standing expert networks. 
The scope of the legal correspondents’ expert meeting will be enlarged to take in a 
broader policy agenda covering legislative and strategic developments as well as 
public expenditure.
To date, the evaluation of national drug strategies has relied both on data provided 
by the NFPs and on specialist information from two technical meetings organised 
in 2008 and 2010. Routine monitoring in this area shows a rapid increase in the 
number of EU Member States that now evaluate their strategy or action plan. It also 
suggests that the methods used for these evaluations are not always optimal and 
could benefit from an exchange of knowledge and expertise between countries. For 
this reason, in 2012, the EMCDDA published European guidelines for the evaluation 
of national drug strategies. In addition, EMCDDA experts provided advice and 
support for the evaluation of different national drug strategies, an activity that will be 
continued in the future.
Another key part of our work in this area is the ongoing support provided in the 
framework of the progress reviews and final evaluations of the EU drug strategy 
and its action plans, and of new drug-related legislation developed at EU level. We 
will provide both methodological assistance and time trends analysis, and, when 
required and possible, develop specific data collection activities for this purpose. 
Close collaboration with the EC and other European agencies will be a key element 
for effective work in this area.
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Over the last five years, we have invested in monitoring drug-related public 
expenditure. The data available are limited, however, and not sufficient to obtain 
a good European picture and make reliable comparisons between countries. As a 
consequence, we have developed a new, more delineated strategy whereby specific 
areas of expenditure will be identified and estimated separately. This approach will 
provide more useful analysis than that given by a cumulative estimate in which the 
constituent elements included are not standardised between countries. It is hoped 
that, by improving estimations in this manner, a more reliable total expenditure 
computation will be possible in the future. This implies not only collecting data in 
different areas but also developing guidelines and sharing knowledge on how best 
to obtain and analyse such data. We will focus on studying the impact of the recent 
economic recession on the content of drug policies.
To ensure that we disseminate the analyses produced in the policy area effectively, 
we will produce a set of short reviews which will address key policy issues or 
provide an illustrative overview of national policy examples.
In 2015, we plan to publish a state-of-the-art scientific review on future drug policy 
challenges in 2015 (EMCDDA Monograph). This monograph will address the key 
issues facing the European drug policy agenda with a perspective geared towards 
future challenges, which are likely to include developing policies in a context of 
austerity, building on evidence, and responding to innovation, social change and 
technological advances. The release of this monograph will be designed to stimulate 
discussions at a major conference planned to review the state of the European drugs 
problem, to be organised in Lisbon in 2015.
Goal: Improve the understanding of European and global policy developments by 
providing relevant and timely drug policy data, analysis and expertise 
Specific objective 6.1: Develop European and global drug policy monitoring and 
analysis
Priority interventions Key results
Review current knowledge on key drug 
policy issues and challenges 
• State-of-the-art scientific review on drug 
policy challenges for the twenty-first 
century (EMCDDA Monograph series)
Examine different models of drug policy to 
provide a better understanding of current 
policy options and support decision-making 
processes 
• Six to ten policy papers published on 
different characteristics of European, 
national and international drug policies 
and on drug policy typologies 
Examine drug policies at the local level • Drug policy paper on drug policies of 
large cities 
Analyse the impact of the economic 
recession on drug policies 
• Drug policy paper on trends in drug-
related expenditure 
Provide data and expertise for the evaluation 
of the new EU drug strategy and its action 
plans, and of other relevant EU legislation or 
activities
• Data and expertise in the areas of drug 
policy evaluation provided at EU level 
Support Member States’ activities in the area 
of drug policy evaluation
• Support and expertise provided on 
request for the evaluation of national drug 
strategies
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Specific objective 6.2: Strengthen European networks in drug law and drug policy 
analysis
Priority interventions Key results
Strengthen network of legal and policy 
correspondents to improve data collection, 
data validation and data analysis in the drug 
policy area
• Improved quality of the data and analysis 
in the drug policy area
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Main area 7: Scientific coordination, research and content support
Overview
An ongoing commitment to improving the scientific quality of our work is a 
prerequisite for fulfilling our role as a centre of excellence for the collection, analysis 
and dissemination of drug-related information. It is therefore a primary objective for 
scientific management and coordination activities.
Europe’s drug problem is complex and multifaceted. A major strength of the 
analysis provided by the EMCDDA is that it is brings together data from across all 
aspects of the phenomenon to provide a holistic and neutral overview with data 
from different perspectives. This requires close coordination between the agency’s 
different scientific units. This is delivered through the scientific coordination structure, 
with each unit having responsibility for a transversal activity as well as a technical 
specialism, and with the work of the individual units being coordinated centrally 
through a ‘Division’ management structure.
This integrated working practice is necessary for internal efficiency. It is required by 
the more integrated approach to communication, in which dissemination issues will 
be taken on board early in the technical product-planning process. It is also required 
to successfully support capacity-building work, both within the Reitox network and 
with external programmes. The scientific coordination team will facilitate the good 
communication and well-coordinated working practices that are essential for the 
success of this work programme.
The agency’s focus on quality assurance will require new internal mechanisms to 
ensure that scientific and methodological standards are defined and met. These will 
be common across the EMCDDA’s scientific work and audited centrally. A related 
task will be to help ensure the continued development, quality and coherence of the 
EMCDDA’s information collection and reporting system. We have recently reviewed 
this and a number of improvements are planned to working practices. Within the 
current perspective of fixed resources, maximum efficiency is required to improve the 
overall quality of information available. Given that the data collection capacity is 
finite and dependent on national activities, ongoing review of existing demands on 
data and careful scrutiny of new requests are needed to ensure that demands on the 
system do not exceed capacity. Moreover, the EMCDDA’s remit is a broad one, new 
areas of interest are developing and resources remain fixed. The sound management 
of scientific activities therefore requires oversight to ensure that the use of resources, 
be they financial or human, are matched to reporting needs and priorities and 
informed by the commitments made in the strategy and work programme.
We will develop a more robust protocol for handling requests for scientific advice 
and opinion. This will ensure that EMCDDA input on important issues is both timely 
and scientifically sound. This will be informed by a framework for grading types of 
information, both in order to provide a measure of data quality and to be able to 
better describe the level of uncertainty inherent in different types of analysis.
The EMCDDA editorial board and product management system support an 
integrated approach to output generation whereby scientific and communication 
issues can be brought together, processes assured and quality control maintained. 
The communication strategy on which this is based is described below (main 
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area 9). Within the scientific units, product creation, in the pre-editing phase, is 
supported by a content coordination and quality assurance system. This reflects 
the composite nature of many EMCDDA products, in which the work of different 
scientific units needs to be brought together into a coherent narrative. Content 
coordination also acts as a quality control mechanism and supports scientific writing. 
It is planned to systematise procedures in this area further, in close coordination 
with the communication team and reflecting the new integrated communication 
strategy. This will be particularly important for ensuring scientific quality control 
aspects in the development of online information resources. We will introduce a 
more systematic peer-review process for all major publications. A more rigorous 
approach will be adopted for the initial outline development of major products 
guided by clearer style and guidelines. The EMCDDA will continue to support the 
production of papers intended for publication in scientific journals. Work in this area 
will be guided by new procedures to ensure that the resources utilised in this area 
are well spent and that outputs produced are of high quality. Priority will be given to 
those analyses in which data held by the EMCDDA have the potential to impact on 
important contemporary scientific debates. Scientific papers will be recognised as 
formal outputs of the agency and detailed in annual work-planning exercises so that 
resource implications and support requirements can be better assessed.
The EMCDDA will continue to formalise and develop its programme of training 
activities and related resources in the 2013–15 period. Training activities developed 
at the EMCDDA cover a broad area of initiatives including academic-orientated 
training, capacity-building projects, specialised training of national experts, training 
initiatives undertaken with other agencies and international organisations, in-house 
traineeship opportunities and resources developed for external audiences. To 
ensure efficiency and minimise costs, an integrated approach is envisaged, with 
common materials developed for multiple purposes, and training activities linked 
where possible to expert meetings. This will be particularly relevant for training 
activities accompanying capacity-building work as it is cost-efficient and can lead to 
networking opportunities. Training materials will be web-based wherever possible to 
maximise their accessibility.
The EMCDDA works very closely with the research community, and EMCDDA 
activities both utilise research findings and act as a catalyst for new research 
questions. We collect and disseminate information on drug-related research activities 
in Europe and assist where possible with scientific networking and publicising 
funding possibilities — with an emphasis on the EU level. Researchers and experts in 
the field have welcomed this accessible provision of information. This approach will 
be maintained and outputs better systematised and integrated within the new web 
format.
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Goal: To produce high-quality scientific work through efficient working practices
 
Specific objective 7.1: Ensure the coordination of scientific activities so that resources 
are efficiently used, objectives are achieved and quality control of outputs is 
maintained
Priority interventions Key results
Improve handling of requests for scientific 
advice and opinion
• Protocol for ‘Handling requests for 
scientific advice’ operational
• Framework for grading evidence 
developed
Develop EMCDDA strategy on training for 
external audiences 
• Strategy developed and implemented 
Ensure the coherence of the overall reporting 
system within a framework for quality 
assurance
• Systemic review: follow-up action plan 
implemented
• Mechanism(s) for coherence, oversight 
and quality control established
• Output-orientated and competitive 
approach to planning and resource 
allocation 
Coordinate training activities • Integrated training strategy developed and 
implemented
• Improved availability of training resources
Support the production of high-quality 
scientific content
• Support provided for content production 
(pre-editing)
• Scientific aspects required for overall 
quality control framework developed and 
implemented
• Peer review system implemented (in 
consultation with Scientific Committee)
• Strategy for supporting scientific 
publishing implemented 
 
Specific objective 7.2: Support drug-related research, audit key developments and 
promote the use of research findings
Priority interventions Key results
Monitor and disseminate developments in 
drugs research 
• Improved online access to EU-funded 
research findings
• Annual audit of important research 
developments 
Provide input to the development of the EC 
research agenda 
• Methodology for advising on research 
priorities endorsed by the Scientific 
Committee
• Input to European Research Area Network 
on Illicit Drugs (ERANID)
• Structured input on research priorities at 
the level of the EU and at the level of the 
Member States 
Further develop collaboration with the 
scientific community through dissemination 
of findings and increased contribution to 
relevant events 
• Increased input, visibility and standing of 
EMCDDA outputs
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Main area 8: Cooperation and collaboration with key partners
Overview
Partnership and effective collaboration is necessary for delivering the overall 
objectives of this work programme. The EMCDDA actively pursues partnerships 
and working synergies with EU institutions and agencies, civil society, international 
organisations, specialised government agencies and third countries.
For activities within the European family the main priorities of work are to support the 
EU policy debate technically through close work with EU institutions; fulfil institutional 
responsibilities; and ensure efficient and productive working arrangements with 
other agencies with an interest in the drugs area. For activities beyond the EU, the 
work is guided by the agency’s mandate and its international cooperation strategy. 
It is also informed by the need to support EU programmes and initiatives or relevant 
international endeavours technically, while recognising that resources are limited 
and that additional activities should not undermine core priorities.
The EMCDDA has provided technical input and review documents to support the 
implementation and monitoring and evaluation of the 2005–12 EU drug strategy 
and its accompanying action plans. We expect that we will be tasked with new 
responsibilities within the new EU policy framework; if so we may need to adjust this 
work programme. The EMCDDA works closely with the Commission, the Council 
and the Parliament within the context of its mandate to provide technical support 
and information. Of particular note here is the input we provided on demand to 
the Horizontal Working Group on Drugs and to bilateral dialogues between the EU 
and third countries. The EMCDDA also supports the work of the EC on an ongoing 
basis, providing technical input in those areas where it is requested. Building on the 
successful work conducted during the 2010–12 period, we remain committed to 
joint work with other EU agencies.
The EMCDDA will also work to improve the dialogue that exists between the 
agency, civil society, national policymaking bodies and relevant technical and 
scientific organisations. Civil society plays an important role in the European drug 
policy debate as well as acting as a service provider in many Member States. It is 
also an important consumer of our information and data provider. We will scale 
up our efforts to report on developments in the civil society area and increase our 
investment in establishing effective channels for communication and information 
exchange. We also recognise that national policymaking bodies are an important 
audience for our work and here again a two-way information flow is desirable, as 
debates within Member States can be of wider interest. To help improve the targeting 
of products, in line with the communication strategy, we will seek to understand 
better the needs of national policymakers and what constitutes effective channels of 
communication for them.
In recognition of the global nature of the drug problem and the value of promoting 
the EU model of policymaking informed by scientifically sound information, 
the EMCDDA pursues technical collaborations with appropriate international 
bodies. Work focuses around developing common reporting standards, sharing 
methodologies and information exchange. The agency is increasingly identified as 
a centre of excellence and a key reference for drug monitoring: its methods, tools, 
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analysis and publications have become the main European reference for regional 
and international organisations.
A more specific area of substantive work that we will develop is cooperation and 
capacity building with countries that represent a priority for EU action, notably 
the candidate and potential candidate countries and the countries covered by the 
European Neighbourhood Policy (ENP). The EMCDDA has a proven track record 
of delivering high-quality capacity-building activities reflecting established reporting 
standards and methods. Activities in this area will be structured around three 
groups. For the candidate countries (the Former Yugoslav Republic of Macedonia, 
Montenegro, Serbia and Turkey) and potential candidate countries (Albania, 
Bosnia and Herzegovina, and Kosovo, under UNSCR 1244/99), new technical 
cooperation project(s) will be implemented in the western Balkan countries, with 
the aim of enhancing the scientific value of drug-monitoring activities. For the ENP 
countries, capacity-building activities will be open to the Eastern partnership and 
the Southern partnership, as well as the Russian Federation. The objective will be 
to support the use of the EMCDDA methods among interested countries, in order to 
improve analysis and reporting. Scientific support will also be provided to other non-
EU countries, such as countries of Central Asia or Latin America and the Caribbean. 
Activities in this area, commensurate with resources, are based around EU regional 
programmes (such as the Central Asia Drug Action Programme, CADAP, and 
Cooperation Programme between Latin America and the European Union on Drugs 
Policies, COPOLAD) or through bilateral agreements.
Goal: To support EU drug policy debate and effective actions and increased 
capacity for reporting on drug use in non-EU countries with an emphasis on 
countries that represent a priority for EU action in the drugs area 
Specific objective 8.1: Coordinate, cooperate and provide technical support at the 
EU level
Priority interventions Key results
Provide technical support to EU policy 
deliberations
• Support for the EC and European 
Parliament (as requested)
• EMCDDA technical backstopping and 
support to policy debate at the Horizontal 
Drugs Group (HDG) and other appropriate 
fora (when requested)
• Support to the EU drug strategy after 
2012 (to be defined)
• Support for the implementation and/or 
monitoring of policy documents: OAP on 
synthetic drugs, HIV/AIDS action plan, EU 
alcohol strategy (as regards polydrug use 
etc.) as required
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Priority interventions Key results
Ensure effective collaboration with other EU 
agencies 
• Working synergies, joint projects and 
information exchanged
• Work programmes and cooperation 
agreements endorsed and implemented
• Effective cooperation with Europol, 
CEPOL, Eurojust, ECDC, EMA
• Participation in the Justice and Home 
Affairs (JHA) cluster
• Framework for cooperation with other 
EU agencies established and developed 
(where appropriate)
Specific objective 8.2: Improve dialogue with policy audience, civil society and 
relevant technical and scientific bodies
Priority interventions Key results
Monitor key developments and improve 
information exchange with civil society 
partners 
• Monitoring and report on key 
developments made by civil society in the 
drugs field
• Improved dialogue and information 
exchanged in relevant areas 
Improve understanding of information needs 
and identification of effective communication 
channels with national policy bodies 
• Better targeting of information products 
and improved communication 
Maintain awareness and identify synergies 
with appropriate technical and scientific 
bodies working in the drugs field
• Overview of activities, information 
exchange, networking with research and 
monitoring centres and, if appropriate, 
joint activities
Specific objective 8.3: Coordinate, cooperate and provide appropriate technical 
input to work conducted by international bodies in the drugs field
Priority interventions Key results
Provide technical input and information 
(in line with the mandate and strategy) to 
international activities 
• EMCDDA contribution to expert meetings, 
international projects, trainings and 
seminars
• Information exchange with international 
partners and regional bodies [including 
UNODC, Joint United Nations Programme 
on HIV/AIDS (UNAIDS), WHO, Interpol 
and WCO, Pompidou Group and CICAD]
Support the development of coherent 
information standards and information 
resources at international level 
• Input provided and, where possible, data 
validation exercises conducted and codes 
harmonised 
Develop and implement joint work with key 
external partners
• Work programmes and cooperation 
agreements endorsed and implemented
• Joint publications produced and published
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Specific objective 8.4: To support capacity development and enhance the scientific 
value of drug-monitoring activities within candidate (CCs) and potential candidate 
countries (PCCs)
Priority interventions Key results
Consolidate institutionalisation of NFPs 
within CCs and PCCs
• Roadmaps for joining the EMCDDA 
adopted by countries
• All countries have officially appointed 
an NFP to the EMCDDA and NFPs are 
functional
Foster scientific cooperation in relation to 
data collection, interpretation and analysis 
and accrue added value from cooperation 
activities
• Better data and better analysis of 
available data
• National reports following the EMCDDA 
guidelines
• Data from CCs and PCCs integrated into 
EMCDDA products
Specific objective 8.5: Support capacity development, information availability and 
exchange with interested ENP and other non-EU countries
Priority interventions Key results
Launch the EMCDDA technical cooperation 
with interested ENP partner countries and 
improve knowledge base
• Information maps and country overviews 
available on the EMCDDA website
• National action plans for drug information 
system (NAPDIS) adopted
• EMCDDA strategic report on drug situation 
in ENP countries
Exchange information, working practices 
and methodology on the identification of 
new psychoactive substances with other 
interested regional and national monitoring 
systems
• Information exchanged
• Increased knowledge base on new 
psychoactive drugs
• Participation of interested countries in the 
Internet snapshot exercise (if appropriate)
Provide ad hoc scientific support to ongoing 
EC regional programmes 
• Scientific support provided to COPOLAD, 
CADAP etc. (subject to resources)
Develop training materials and training 
modules on EMCDDA standards
• Reitox academy summer course
• Handbook II on key indicators published
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Main area 9: Communicating the EMCDDA’s findings to external 
audiences
Overview
Independent, science-based information is a vital resource to help Europe understand 
the nature of its drug problems and better respond to them. Communication is one 
of our core activities in our role as information agency and the reference point 
on drugs in Europe. Two important elements will reshape our work in this area in 
2013–15. On the one hand, this will be a time of budgetary austerity in Europe, 
which will bring with it a heightened need to ensure increased cost-effectiveness 
of our operations. On the other hand, we will be facing the backdrop of a rapidly 
changing communication landscape, requiring the agency to respond with timely 
content, be attentive to emerging needs and deliver its information using an 
expanding set of communication tools.
Communication work will be developed across several cross-cutting themes and 
guided by the integrated communication strategy developed in 2012. The thrust of 
this strategy is to ensure that communication activities are not an isolated function 
at project-end, but an integral part of the agency’s scientific and technical activity. 
Clarifying relevance of content and its intended audience at product conception 
phase will facilitate timely and cost-effective follow-up.
An integrated communication strategy to support:
• relevant, timely and responsive analysis of the drug situation, through focused 
and dynamic production of information with early discussion of audience and 
channel;
• efficiency, through upstream guidance on the communication tool that can 
provide the highest impact for the content in question, also leading to more cost-
effective choices;
• a more customer-orientated approach, by regularly analysing audience needs 
and preferences and ensuring emphasis is shifted appropriately.
Part of the added value of the agency is to interpret complex information into 
meaningful and useful messages for policymakers, scientists and researchers, 
practitioners and the general public. Improving how we communicate our findings is 
a key strategic aim for 2013–15, which is supported by some core communication 
values: quality, consistency, efficiency, relevance and transparency. Activities to 
support this aim range from the way we structure and share information to the way 
we visualise our data.
Developing communication services in light of the digital evolution and social web is 
a key challenge and includes dealing with demands for transparency and engaging 
actively with audiences. Building and maintaining trust is a core consideration when 
adopting a new approach.
We have a well-established set of communication channels and tools that 
we use to engage with key stakeholders and target groups, including web 
publications and print products, social media, audiovisual, media relations, face-
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to-face communication (conference, visits etc.), marketing (branding, reputation 
management, promotions etc.), general enquiries desk and targeted distribution. 
We will review the channels used for each output and target audience to ensure that 
they are appropriate. We will look to expand tools in line with needs identified, for 
example e-books and post-PC tools. We will work to strike a better balance between 
web-based and printed products. Streamlining of some product lines and a redesign 
of others will be necessary to ensure content relevance and coherence for agency 
results.
We will respond to the need for active communication by participating in 
conferences and meetings and will ensure that the knowledge imparted is shared 
with a wider audience. Particular emphasis will be placed on ensuring better 
dissemination of results from our expert and technical meetings. We will promote 
communication as a responsibility for all staff and provide ongoing training for 
this task. We will work with NFPs to further develop their role as communicators of 
EMCDDA knowledge.
In 2015, we will organise an international conference on drug policy challenges 
in the twenty-first century that will bring together the best experts in the drugs area. 
The conference is an integral part of the work programme and is timed to provide 
Europe with an audit of the state of play of the situation, responses and policy 
developments. This event will provide an ideal opportunity to present the EMCDDA’s 
work in the context of important ongoing political developments and future 
challenges. It will also be a useful forum to interact with our target audiences and 
solicit feedback from them on our work.
The priority to increase the impact of the agency’s online presence noted throughout 
this document requires action on several fronts. We will put in place a web 
governance strategy that sets out the procedures and responsibilities for maintaining 
a web resource that is up to date and quality controlled. We will introduce a more 
sophisticated content management capability to facilitate publishing and managing 
content. We will develop a set of web-based products matching our revised 
reporting processes. For example, a streamlined and better-focused printed Annual 
report is foreseen within the revised annual reporting package, which will provide a 
window into a comprehensive set of web-based resources. We will also ensure that 
web development activities are adequately resourced, and will invest in writing and 
conceptual skills.
The EMCDDA will evaluate the impact and effectiveness of communication activities, 
taking into account learning from consumer and target audience research, media 
monitoring and analysis, output analysis (e.g. understanding of messages), web 
traffic analysis, web user surveys, etc. In particular, we will seek to gain better 
insight into our professional influence (outreach) and conduct return on investment 
(ROI) and cost–benefit analyses (linguistic policy).
The priority to match communication services better to the overall EMCDDA strategy 
foresees improving knowledge – i.e. helping staff match their work to product 
types and training users better as regards the communication resources available 
— and improving multi-year planning of outputs with better phasing for content 
development, peer review, editing, production and launch. The investments outlined 
above cannot be accommodated without identifying some areas for disinvestment. 
These include reduction in printed products/print runs; revision of linguistic policy 
(relevant outputs in relevant languages in line with audience needs, paying attention 
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to quality over quantity); reduction in distribution costs (development of electronic 
mailing lists); and adopting an approach based on real needs for library resources 
and distribution.
Goal: EMCDDA information and analyses of high quality reach their intended 
audience in a timely and cost-efficient manner
Specific objective 9.1: Implement the integrated communication strategy and action 
plan (adopted in 2012)
Priority interventions Key result
Develop procedures to integrate 
communication perspective at product 
conception
• Improved planning and shaping of 
products upstream
• Better-paced and -targeted launches
Redesign product range to reflect new 
EMCDDA strategy and work programme 
(brand refresh)
• Balanced products mix with cost and 
efficiency savings
• Refreshed product lines with improved 
design and format 
Implement revised linguistic policy • Better quality and relevance of multilingual 
products
• Increased value from investment in 
translation (based on cost benefit and ROI 
analyses) 
Implement revised media relations strategy • Enhanced EMCDDA exposure to media 
around the world (through an up-to-date 
strategy reflecting developments in new 
media and the agency’s international 
outreach) 
Match communication and dissemination 
channels to needs and preferences of target 
audiences 
• Improved impact through differentiated 
use/mix of communication channels
• Interactive communication channels
• Content adapted to different 
communication channels (tone, language)
• Increased use of electronic means for 
dissemination
• Various alternatives to physical distribution 
introduced and promoted
Monitor and evaluate the impact of 
communication activities
• Better knowledge of outreach and impact 
gained in order to inform future EMCDDA 
strategies
Specific objective 9.2: Publish high-quality and timely products in line with targets 
committed to in the 2013–15 work programme
Priority interventions Key result
Assure publication, launch and dissemination 
of EMCDDA products
• Planned products published, launched and 
disseminated
• Improved internal procedures and tools to 
better plan and monitor production
Reconceive and reshape printed Annual 
report
• Streamlined and electronically integrated 
Annual report produced and launched in 
the first half of the year
• More efficient use of resources
From strategic vision to getting results
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Specific objective 9.3: Increase the relevance and impact of the EMCDDA’s online 
presence
Priority interventions Key result
Develop web content in line with integrated 
communication strategy 
• Website is up to date and reflects the 
EMCDDA’s knowledge on the drug 
situation in Europe
Increase interactivity and targeted approach 
of the website
• New areas targeted at specific audiences 
introduced
• More user-centred access to information 
Introduce new quality assurance system for 
web content
• Web governance strategy implemented 
and content quality assured
• Better content management tool to monitor 
updates and modifications in place 
Install new content management tool and 
migrate content
• Content migrated to new content 
management tool
• Better-linked and -integrated web content
• Improved findability of content 
Specific objective 9.4: Enhance the EMCDDA’s reputation and recognition as the 
European central reference point for drugs information
Priority interventions Key result
Organise European drugs conference in 
2015 
• Successful conference informing on the 
state of drug policy in Europe 
Ensuring visibility of EMCDDA across 
multiple communication platforms 
• Awareness raising and positioning of the 
EMCDDA’s work, results and scientific 
expertise
• More active approach to providing 
publications and information at 
international events and conferences
Continue to build sound contacts and 
relations with journalists and provide media-
friendly information with clearly defined 
messages
• High-quality press products and 
appropriate EMCDDA presence in relevant 
media
Public information service • Efficient public information desk operates 
in line with guidelines set by the European 
Ombudsman
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Main area 10: Governance, management and networks
Overview
The core focus of governance work in 2013–15 is to provide the direction 
the agency needs to perform the tasks set out in its Regulation and achieve its 
objectives. This is even more essential within the current dynamic EU political and 
financial environment, which requires the agencies to strengthen their strategic and 
operational capacity and develop a more performance-based organisational culture.
Over the next few years, we will develop a strategic development framework for the 
EMCDDA’s work. This includes aligning the vision, mission and core organisational 
values with the top-level commitments and new medium- and long-term developments 
identified in this work programme. To this end, one of the priorities for 2013–15 
will be to review the EMCDDA’s ethical and organisational values and reshape the 
organisational culture around new values.
In order to facilitate the strategic decision-making process and ensure good 
governance, we will provide ongoing support to the Management Board by having 
regular contacts with the Board members, organising the statutory meetings and 
preparing documents to support their work. Both the Management Board and the 
Director rely on the independent expertise and advice of the Scientific Committee, 
which is the cornerstone of the agency’s scientific quality and standing. In 2014, 
the current committee will reach the end of its mandate and the profile of the new 
committee will be reassessed in light of the EMCDDA’s current and future areas of 
work. Increased support for the agency’s scientific activities is foreseen, including 
peer review of some of the products, advice to staff and feedback on findings.
Successful implementation of the strategic decisions made by the Board requires 
effective management organisation and practices. Of utmost importance will be 
to ensure that the agency’s resources are used in the most efficient, effective and 
economical manner. Given the scenarios of budget constraints ahead, we will 
give special consideration to rationalising use of agency’s resources and to further 
promoting cost-effectiveness, accountability and transparency. This is a top-level 
commitment for 2013–15 and the EMCDDA Director will hold the key role, in 
particular by orienting and supporting the units in performing their tasks and 
ensuring that the agency’s organisational structure remains appropriate.
At operational level, we will follow up on the processes and procedures used for 
the implementation and control of activities and will review the internal document 
management process, in order to ensure that it is secure, efficient and compliant with 
the applicable legislation.
Improving efficiency in our operations to get the best results is a core focus for 
the next three years. We will further strengthen the strategic planning, monitoring 
and reporting capacity to achieve this. Our main priority will be to build an 
integrated performance measurement system, allowing the EMCDDA to monitor 
its achievements and adjust its operational objectives and processes. The design 
of the performance measurement system will be based on our organisational 
needs, including the need to ensure full transparency of and accountability for our 
operations towards the EMCDDA’s stakeholders and the general public. In order 
to generate continuity and optimise use of resources, we will make full use of the 
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existing monitoring mechanisms. There will be two major components developed 
in parallel: the first will focus on defining performance indicators for all areas of 
work; the second will be the design of the monitoring and evaluation system used to 
support the collection, analysis, interpretation and reporting of performance data. 
To the extent possible, and in line with the principles of activity-based budgeting 
(ABB) and activity-based management (ABM), the system will integrate operational 
and financial data. This task will involve joint work between the operational and the 
financial planning actors and will allow the agency to analyse the results achieved in 
light of the resources deployed, and hence to measure its efficiency and find the best 
options to improve it.
In the area of the internal control system and risk management, an ongoing task will 
be to maintain an updated repository of the state of compliance with the EMCDDA 
Internal Control Standards (ICS) for effective management and control. This effort 
will be combined with regular updates of the central risk register already introduced 
in 2010. The implementation of our business continuity plan will be an important 
development. We will continue the thorough verification of financial transactions, to 
ensure that they are made in accordance with the relevant regulatory requirements, 
including sound financial management. Best practices on cost-effectiveness of 
operations will be promoted as appropriate. The already existing monitoring effort 
will be better documented with a view to identifying possible weaknesses or areas 
for improvement in the quality of the ICS.
The good cooperation with the European Court of Auditors and the EMCDDA’s 
Internal Audit Service (IAS) will continue, with a view to taking stock of 
recommendations arising from audits in areas identified as of strategic importance. 
Appropriate implementation and follow-up of such recommendations will continue to 
be done along suitably designed action plans.
Goal: The EMCDDA attains good performance in carrying out the tasks set out 
in its Regulation and achievement of its objectives. This will be accomplished 
through good governance and efficient management and leadership, supported by 
enhanced planning, monitoring and reporting and an effective internal control and 
risk management system 
Specific objective 10.1: Ensure good governance to provide the strategic guidance 
and direction for the work of the EMCDDA
Priority interventions Key results
Implement strategic decision-making process 
at the level of the Management Board 
• Multi-year and annual work programmes, 
budget, reports of activities and other key 
decisions adopted
Provision of support and guidance by the 
Scientific Committee, to further enhance the 
scientific quality of the EMCDDA’s work
• Improved scientific work, through 
guidance and peer review of outputs
• New Scientific Committee in place
57
Specific objective 10.2: Ensure efficient management and leadership to support 
achievement of results and efficient use of resources
Priority interventions Key results
Implement sound management organisation 
and practices 
• Further improved working structure, 
organisation and methods, to support 
efficient implementation of activities
• Annual work programmes implemented 
as planned and/or measures to improve 
performance taken, when necessary 
Specific objective 10.3: Improve and implement the agency’s strategic planning 
and programming cycle processes, to support timely delivery of results and sound 
decision making concerning allocation of resources and actions to be taken to 
enhance performance
Priority interventions Key results
Design and put in place an integrated 
performance measurement system 
to allow EMCDDA to track progress 
of its achievements better and detect 
implementation challenges in a timely way
• Performance measurement system 
operational, including performance 
indicators defined and monitoring and 
evaluation system in place
Prepare the documents required by the 
strategic planning and programming cycle
• 2013–15 annual work programmes, 
management plans and general reports of 
activities
• 2016–18 strategy and work programme 
Specific objective 10.4: Ensure effective internal control and risk management system
Priority Interventions Key results
Implement sound internal control system • Full compliance of EMCDDA operations 
with the existing EU regulations and 
practices
• Business continuity plan adopted and 
implemented
The Reitox network
Data collection and reporting are the main tasks of the Reitox network, and NFPs 
are considered the national authorities for providing the EMCDDA with information. 
The performance of the NFPs is influenced by the level of institutional and financial 
support available and the development of information sources and reporting 
capacity at national level. The current financial perspective may present challenges 
in both these areas. The EMCDDA works closely with NFPs to provide a framework 
for quality reporting using comparable tools. Information is collected through an 
annual reporting package consisting of national reports, standard statistical tables 
and structured questionnaires. During the next three-year period there will be a need 
to review, and in some areas adjust, the current reporting framework to be sure it 
remains fit for purpose.
The main priorities for EMCDDA in its work with NFPs during the new work 
programme will be (1) consensus building to refine the existing reporting frameworks 
and agree the annual reporting package, including revisions when necessary; (2) 
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strengthening the Reitox network and in particular its role at national level as a high-
quality provider of information; (3) developing an integrated approach to capacity 
development and quality assurance, in the context of the overall strengthening of the 
quality assurance framework of the EMCDDA; and (4) continuing to strengthen the 
management and organisation.
Specific objective 10.4: Ensure that the Reitox network is efficiently managed and 
structured to meet future needs and requirements
Priority interventions Key results
Agree the annual reporting package and 
necessary developments to the overall 
reporting framework 
• National reporting package agreed and 
implemented
• Reporting framework adapted to work 
programme requirements
Strengthen the Reitox network at national 
level as a high-quality provider of 
information 
• Accreditation programme adopted and 
tool for the self-assessment of strategic and 
operational capacity of NFPs implemented
Develop an integrated approach to 
capacity development and to quality 
assurance
• Quality assurance framework in place
• Coordinated Reitox training and support 
activities in place 
Strengthen the management and 
organisational processes and procedures 
• Organisational structures and processes 
configured to meet future needs
• The ‘Reitox week’ meeting of Heads of focal 
points to provide a vehicle for exchange, 
training and development
• More capacity for delivering added value at 
national level as an information provider 
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Main area 11: Administration — supporting core business
Overview
The existence of effective administration and support services is an essential 
requirement necessary to support the scientific and technical work programme of 
the Centre. Our main commitments in this area are to enhance efficiency, to further 
develop sound management of the resources available and to provide service-
orientated administrative support to the agency’s operations.
In the financial management area, we will focus on aligning the EMCDDA’s financial 
rules to the revised EU financial regulations and updating the relevant processes. We 
will strive to improve efficiency in financial transactions and procurement operations. 
The introduction of digitised tools and processes such as the electronic workflow 
for financial transactions, the information technology-based tool for staff missions’ 
management and the management of meetings-related transactions will contribute to 
achieving this, as will rationalising and optimising tendering processes.
Improving overall execution of the budget is also a key aim. This involves timely 
preparation and use of budget planning and management tools (such as draft 
budget, amending budgets and budget transfers) as well as further developing the 
EMCDDA’s ABM and ABB system.
We will improve the quality of the EMCDDA’s accounting management and 
reporting activities by developing the accounting of assets with new solutions 
integrated into statutory accounting principles (SAP)-based accounting systems.
In human resources (HR) management, we will concentrate on providing the 
conditions for staff to deliver results efficiently, based on the principles of excellence 
and transparency. A first priority is to align EMCDDA HR processes and policies to 
the forthcoming reform of the EU staff regulations. This will require preparing and 
implementing rules and training staff on the main aspects of the reform. Further 
digitising the HR management processes is another priority to increase efficiency. 
We will use training opportunities to develop the EMCDDA’s working and production 
capacity. The needs and priorities for training will be regularly updated, and 
dedicated training for staff (including management) will be developed. Defining a 
clear framework for staff career development is also an important intervention.
In the area of logistics and infrastructure, we will concentrate on optimising the 
use of the available facilities, equipment and infrastructure and ensure a healthy 
working environment for the agency’s staff. We will prioritise safety at work, sound 
environmental management and security in the buildings, including reducing utility 
costs and promoting use of renewable energy.
From strategic vision to getting results
60
EMCDDA 2013–15 strategy and work programme
Goal: Ensure effective and efficient allocation and management of financial and 
human resources and assets, through further rationalising internal processes, while 
developing the quality of services and support provided
Financial and budget management, and accounting
Specific objective 11.1: Enhance effectiveness and efficiency in the execution of the 
budget and in the management and accounting of financial resources
Priority interventions Key results
Align the EMCDDA financial rules to the 
revised EU financial regulation and ensure 
their implementation 
•  EMCDDA revised financial rules and 
processes defined in accordance with the 
forthcoming revision of the relevant EU 
legislation, adopted and implemented 
Further improve effectiveness and efficiency 
of financial transactions (payment process) 
and procurement processes
•  Payments successfully made within the time 
limit stipulated in the financial rules
•  Average deadlines for payment reduced 
(compared with 2011)
•  Rationalised and optimised tendering 
processes
Ensure effective and timely preparation and 
use of budget planning and management 
tools in line with EMCDDA priorities and 
constraints and in accordance with ABM/
ABB principles
•  Adoption of the budget for year N and 
preliminary draft budget for year N + 1 
by the end of year N – 1 in line with ABM 
and ABB system in place
•  Budget forecast for year N + 2 (at level of 
chapter)
•  High budget execution rate maintained
Develop customised reporting on budget 
execution
•  Stakeholders needs met through regular 
statistical reports and customised reports 
on budget execution
Improve the accounting of EMCDDA assets, 
and further define the conditions and 
requirements for the function of accounting 
officer at the EMCDDA according to 
applicable financial rules 
•  Improved system in place for accounting 
of assets
Human resources management
Specific objective 11.2: Maximise efficiency and effectiveness of HR management at 
the EMCDDA
Priority interventions Key results
Align EMCDDA HR processes and policies 
to the forthcoming reform of the EU staff 
regulations
• Implementation of the ‘reformed’ staff 
regulations without hampering the 
continuity of the main HR processes (i.e. 
payment of salaries, carrying out of 
annual processes such as performance 
appraisal of staff, promotion/
reclassification exercise)
Further digitise HR management processes 
through the development of information and 
communication technology tools to increase 
their efficiency and effectiveness
• Additional HR processes digitised further 
to the introduction of the HR database and 
e-recruitment tool
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Priority interventions Key results
Develop career paths by relying on the 
concept of ‘job families’ to define a clear 
framework for career development and 
effective management of expectations
• Career paths in place for managerial and 
non-managerial positions
Further develop EMCDDA working and 
production capacity by maximising training 
opportunities for EMCDDA staff
• Training initiatives reflect EMCDDA 
working priorities and need for improved 
managerial capacity
Infrastructure and logistics
Specific objective 11.3: Ensure a healthy working environment and further reduce 
utility costs by optimising the use of the available facilities, equipment and 
infrastructure
Priority interventions Key results
Ensure safety at work, sound environmental 
management and security in the buildings, 
including reducing utility costs and 
promoting use of renewable energy
• Reduction of costs for utilities and 
contracted services
Provide a suitable working environment and 
related services, and improve efficiency and 
effectiveness through promoting a customer-
orientated approach
• Compliance with applicable standard 
requirements for space allocation, meeting 
and mail handling
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Main area 12: Information and communications technology
Overview
Information and communications technology (ICT) activities need to support the 
agency’s core development objectives and to guarantee the smooth operation of all 
up and running services, including corporate application hosting and management 
of the data centre.
In times of swiftly developing technologies and of the agency’s growing 
expectations, applying best practices in terms of ICT governance and investment 
management is at the core of the planning process. The governance of ICT 
comprises different areas: business architecture development and its technical 
implementation; service management; project evaluation and project (and activities) 
portfolio management.
With regard to the technical infrastructure, the core objective will be to ensure 
well-planned maintenance and evolution of the EMCDDA’s technical environment. 
In practical terms, this will lead to the planned replacement of central server 
components, network equipment and standard software.
In relation to ICT service management, we will continue to introduce formal 
procedures in various aspects, to ensure service availability and to leverage the 
advantages associated with any modifications, also considering the principle that 
services are the object of life-cycle management.
Concerning project (activities) portfolio management, in line with best practice, 
as described in the recommendations following an IAS risk assessment and the 
EMCDDA risk register, it is essential to engage the executive level of EMCDDA 
management.
The newly established ICT Steering Committee currently oversees the main priorities 
and activities. The direction it gives to the ICT work programme will be formalised 
with defined and formal criteria in order to arrive at an annual ICT Project (and 
activities) Portfolio aligned to EMCDDA strategies, while ensuring smooth running of 
all existing services, as well as steering and endorsing core ICT strategies.
All the areas of ICT governance are meant to support the EMCDDA business 
requirements, both for existing services and for those reflecting new or changed 
objectives. The pillar work processes of the agency, including data collection and 
data analysis, the development and dissemination of the EMCDDA products, and 
governance processes, have to be taken into account, and constitute the majority of 
the priority interventions listed below.
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Goal: Support the agency in achieving its objectives by providing high-quality and 
efficient ICT services 
Specific objective 12.1: Develop and maintain ICT solutions and tools to support the 
EMCDDA’s work, while applying best practices and standards of ICT governance, 
planning and service management
Priority interventions Key results
Develop and maintain instruments for 
supporting core business 
• Infrastructure for the annual drugs data 
collection and analysis functional and 
further developed, reflecting the evolution 
of the drugs data set and its protocols
• Best practice portal roadmap 
implemented, resulting in new portal fully 
integrated in the agency’s work process
• New EDND conceptualised and 
operational
• Roadmap for the development of a 
collaborative content editing platform
• New web content management tool 
implemented
Implement ‘Business and information 
architecture management’ programme
• First complete versions of the business and 
information architectures 
Implement ‘Technical services management’ 
programme
• Formal definition and adoption of a 
service catalogue 
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Risk assessment
The main risks posed to the EMCDDA’s activity and achievement of objectives during 
the course of the 2013–15 work programme are summarised below.
A. External risks with a direct link to specific fields of annual work 
programmes
 — Tightening of the already visible budget constraints faced by the EMCDDA:  
Whilst sizeable cuts in the EC grant appear to be unlikely, it can be expected 
that the present budget situation at EU level will not improve significantly in the 
years to come, implying that (at best) our present budget constraints will not 
ease for the foreseeable future. Should this risk materialise, the following course 
of action should sequentially be envisaged: (a) to reduce support to partners 
for non-core tasks and activities, (b) to delay or postpone developmental work, 
support and capacity-building activities, (c) to reduce analytical work and 
development of transversal products and (in a worst-case scenario) (d) to lower 
the scope and/or quality of planned outputs.
 — Emergence of specific supplementary requests from EU institutions to provide 
technical support for the implementation of EC programmes and actions:  
In such a case, priorities would have to be reviewed along the lines described 
in the point above, notably by delaying or downsizing certain projects in this 
area and reallocating resources appropriately. The same approach would have 
to be followed should there be supplementary requests for expertise in specific 
domains arising from Member States and third parties.
 — Lack of sufficient funding for the Reitox NFPs in certain Member States, which 
might have a negative impact on their capacity to comply with their reporting 
obligations towards the EMCDDA:  
This risk, which has already materialised in the past, could be compounded 
by lack of adequate funding for information collection in a Member State as a 
whole — that is to say upstream of the NFP — thereby affecting its capability 
to provide reliable information to the EMCDDA. Should this risk materialise, 
priorities assigned to the particular NFP(s) affected would have to be reviewed, 
in order to preserve availability of core information.
 — Unauthorised use or misuse of EMCDDA products by external entities, for 
purposes other than those pursued by the agency, such as for commercial and 
profit-making activities:  
Such abuses might entail reputation risks to the EMCDDA, notably if the contents 
of the original publications were modified or rendered incomplete or inaccurate 
and the agency were cited as the editorial source. This risk materialised at the 
beginning of 2011 as far as violation of copyrights is concerned. Mitigating 
measures such as warnings to entities violating copyrights, clearer disclaimers 
in the EMCDDA publications prohibiting use for any commercial purposes 
and tighter controls on the downloading of our external products have been 
envisaged and ought to be applied in case of need.
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B. External events that might negatively impact the implementation of 
the work programme as a whole
 — Occurrence of natural catastrophes such as major earthquakes (possibly leading 
to tsunamis), landslides or floods:  
This risk exists because of the location of the EMCDDA’s facilities, bordering 
the River Tagus and in a seismic activity area. If a worst-case scenario (a 
major earthquake) were to occur, emergency actions carried out under a 
comprehensive business continuity plan would have to be implemented in a 
timely manner. Even so, some disruption of EMCDDA activities would most 
probably ensue, the respective duration being dependent on the severity of the 
catastrophe and the promptness of aid received from public and/or private 
sources. 
The following mitigating measures have been envisaged to deal with the risks 
mentioned above:
• As far as floods are concerned, improvements regarding the protection of 
the building (including garage) shall be implemented in agreement with 
the respective owner, the Administration of the Port of Lisbon. Efforts have 
already been made but have so far not yielded concrete results; efforts 
should therefore be continued until sufficient protection is guaranteed.
• A very comprehensive insurance contract, covering, inter alia, adverse 
effects arising from earthquakes, landslides and floods, is in force and would 
provide financial compensation in case these events materialise.
 — Terrorist attacks and social unrest, the latter linked to a possible deterioration of 
the country’s socio-economic situation: 
This risk, although considered to be low, in view of Portugal’s peaceful record 
in this respect, should not be disregarded altogether. The EMCDDA insurance 
policy covers damages caused by this kind of event, which is a measure that has 
so far been considered adequate to deal with this risk.
C. Internal risks
C.1. Information technology area
A comprehensive set of governance, technical and security risks in the ICT sector 
has been identified and assessed; consequently, adequate mitigating measures have 
been either taken or proposed in order to tackle these risks. A suitable action plan 
has been defined and implemented internally, aimed at reducing residual risks to 
tolerable levels. The main risks still outstanding and areas where progress is required 
are very briefly summarised below:
 — As regards governance: (a) sound investment decisions will be further pursued; 
(b) ICT projects management should be improved; (c) licensing and asset 
management procedures could be strengthened; (d) ICT applications deployed 
in production should be better tested; and (e) times of response from ICT unit in 
cases of emergency should be shortened.
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 — As regards technical risks: (a) software configuration should be improved; (b) 
patching procedures should be made more consistent; (c) business continuity 
and recoveries in cases of incidents and disasters should be ascertained more 
effectively; and (d) security violations of our ICT systems should be reduced.
All in all, the progress envisaged in the areas above is expected to contribute 
towards obtaining better ‘value for money’ from ICT purchases, enhanced daily 
effectiveness of the ICT systems in place, a quickening of the response times in cases 
of disaster or emergency and, last but not least, the reduction of security violation 
risks.
C.2. Unexpected departure of key staff members
The risk exists that replacement could be difficult in some cases. A number of 
mitigating measures have been consistently adopted and further action in this regard 
shall be implemented as already planned: (a) the reinforcement of staff training 
initiatives; (b) a stronger pursuance of stable contracts with key staff (notably in 
scientific areas); (c) better development of tasks of a transversal nature (with a view 
to fostering sharing of knowledge and expertise); and (d) optimising recruitment 
planning.
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List of abbreviations and acronyms
ABB activity-based budgeting
ABM activity-based management
CADAP Central Asia Drug Action Programme
CC candidate country
CEPOL European Police College
CICAD Inter-American Drug Abuse Control Commission
COPOLAD Cooperation Programme between Latin America and the European Union 
on Drugs Policies
COSI Council on Internal Security of the European Union
DRID drug-related infectious diseases
EC European Commission
ECDC European Centre for Disease Prevention and Control
EDND European database on new drugs
ELDD European legal database on drugs
EMA European Medicines Agency
EMQ European Model Questionnaire
ENFSI European Network of Forensic Science Institutes
ENP European Neighbourhood Policy
ESPAD European School Survey Project on Alcohol and other Drugs
EU European Union
EWS early-warning system
EQUS EU framework for minimum quality standards and benchmarks in drug 
demand reduction
GPS general population survey
HDG Horizontal Drugs Group 
HR human resources
IAS Internal Audit Service
ICT information and communication technology
IPA Instrument for Pre-Accession Assistance
JHA Justice and Home Affairs group, European Commission
KI key indicator
NAPDIS National action plans for drug information system
NFP national focal point
OAP operational action plan
PCC potential candidate country
PDU problem drug use
PhV pharmacovigilance
ROI return on investment
SAP statutory accounting principles
TDI treatment demand indicator
UNAIDS Joint United Nations Programme on HIV/AIDS
UNODC United Nations Office on Drugs and Crime
WCO World Customs Organization
WHO World Health Organization
European Monitoring Centre for Drugs and Drug Addiction
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About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
is one of the European Union’s decentralised agencies. Established in 1993 
and based in Lisbon, it is the central source of comprehensive information on 
drugs and drug addiction in Europe.
The EMCDDA collects, analyses and disseminates factual, objective, 
reliable and comparable information on drugs and drug addiction. In doing 
so, it provides its audiences with an evidence-based picture of the drug 
phenomenon at European level.
The Centre’s publications are a prime source of information for a wide range 
of audiences including policymakers and their advisers, professionals and 
researchers working in the field of drugs, and, more broadly, the media and 
general public.
The EMCDDA’s three-year work programme and strategy sets out the agency’s 
objectives and expected results for the medium term.
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